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Alternative cleavage and polyadenylation (ApA) is most often viewed as the selection 
of alternative pA signals in the 3' UTR, generating 3' UTR isoforms that code for the 
same protein. However, ApA events can also occur in introns, generating either non-
coding transcripts or truncated protein-coding isoforms due to the loss of C-terminal 
protein domains, leading to diversification of the proteome. Due to lack of a study that 
characterizes the intronic polyadenylation isoforms on a genome wide level, we 
decided to investigate the cell type specificity and potential functional consequences 
of isoforms generated by intronic ApA. We therefore carried out an analysis of 3'-seq 
and RNA-seq profiles from chronic lymphocytic leukemia (CLL) and multiple 
myeloma (MM) samples as compared to mature human B cells (naïve and CD5+) and 
plasma cells, respectively, together with our previous 3'-seq atlas generated from a 
wide variety of tissues and cell lines. We found that in more than 20 percent of human 
genes, intronic polyadenylation (IpA) sites are used to generate alternative 3' ends. 
This analysis shows that IpA is a normal and regulated process, most widely used in 
immune cells. IpA events are enriched near the start of the transcription unit, yielding 
non-coding transcripts or messages with minimal coding sequence (CDS). The 
	expression of truncated mRNAs contributes to proteome diversity in normal cells. 
However, we found that cancer cells can take advantage of this mechanism to mimic 
genetic mutations. Many genes with truncating mutations in CLL express IpA 
isoforms. Cancer cells lacking genetic aberrations can disrupt IpA to generate 
truncated mRNAs. These IpA isoforms potentially have similar functional outcome as 
truncating mutations. In this study we unravel a new mechanism by which cancer cells 
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A key problem in molecular biology is the dissection of the different mechanisms that 
regulate co-transcriptional and post-transcriptional mRNA biogenesis. Decades of 
research has elucidated some of the molecular processes for the generation of a mature 
mRNA that can be efficiently transported to the cytosol from the nucleus where it can 
be translated into a protein. With the advent of next generation sequencing 
methodologies there has been increased focus on the characterization and regulation of 
these process, namely capping, splicing and cleavage and polyadenylation. The 
technological advances made in the recent years have established cleavage and 
polyadenylation as a crucial layer of gene regulation. Cleavage and polyadenylation 
precisely defines the 3' end of the transcripts in a two-step process: i) endonucleolytic 
cleavage of the transcribed transcript by the molecular machinery after the recognition 
of a functional poly (A) site, followed by ii) the addition of untemplated adenosines 
(polyA) at the 3' end of the transcript. This co-transcriptional processing is necessary 
for protein expression and is important for the nuclear export, stability, and translation 
of the transcript. 
 
Discovery of poly (A) tails at the 3' end of mature mRNAs marked the beginning of 
discovery of the machinery that defines 3' ends of the transcripts along with its key 
players (Lim and Canellakis 1970). This observation of poly (A) tracts at the end of 
the transcripts was followed by studies that made use of the powerful Sanger 
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sequencing technique to identify a common sequence AAUAAA within 20-30 
nucleotides (nt) of the start of the poly (A) tail (Proudfoot and Brownlee 1976). 
Subsequent experiments focusing on mutation of this hexamer sequence signal, 
referred to as the poly(A) site (pAS), further illustrated that the presence of this signal 
is absolutely critical for an efficient 3' end polyadenylation (Fitzgerald and Shenk 
1981). It has been shown that variants of AAUAAA also function as pAS. Apart from 
the hexamer signal, other cis elements are required to reconstitute a functional pAS. 
Presence of U- or GU- rich elements dowsnstream of the poly (A) signal enhances the 
3' end formation (Gil and Proudfoot 1984). The next breakthrough in the 
understanding of 3' end processing came with the purification of two protein 
complexes: cleavage and polyadenylation specificity factor (CPSF) and cleavage 
stimulatory factor (CstF) (Proudfoot 2011). These two key complexes have been 
shown to recognize the pAS followed by the endonucleolytic cleavage of the 
transcript. Further studies reconstituted the whole cleavage and polyadenylation 
machinery (C/P machinery) to be composed of 15-20 core polypeptides, four protein 
complexes and many single proteins (Tian and Manley 2013). CPSF-160 has been 
shown to interact with the pAS while while CPSF-73 is responsible for the 
endonucleatic cleavage of the pre-mRNA (Mandel et al. 2006).  It was also established 
that the processing of 3' end of the transcripts is separate from the actual Pol II 
transcriptional termination. It was further shown that efficient 3' end processing is 
critical for transcription termination. 
 
As the phenomenon of 3' end processing was being pieced together, further studies 
showed that there are eukaryotic genes that possess multiple functional pAS in their 3' 
UTRs and that the usage of these alternative pAS resulted in transcripts that differed in 
their 3' UTR lengths. This phenomenon of usage of alternative pAS is referred as 
	 3	
alternative cleavage and polyadenylation (ApA). One of the first few examples that 
established the presence and usage of the alternative pASs was in the mouse 
dihydrofolate reducatase (DHFR) (Frayne et al. 1984). DHFR has been shown to 
express mRNAs with identical 5' ends but different 3' end through usage of alternative 
pAS in a growth dependent manner (Kaufman and Sharp 1983). Another example of a 
gene that exhibits ApA is eukaryotic initiation factor 2α (eIF-2α) where the usage of 
the alternative pAS is regulated across different tissues. By the end of the 20th century 
there were multiple independent studies establishing regulation of ApA in around 130 
genes (Edwalds-Gilbert et al. 1997). Different studies showed the ApA isoforms of 
these genes to be highly regulated across different tissues as well as in different 
cellular conditions. These genes were shown to produce mRNAs with different 3' ends 
via methods like northern blots or nuclease protection assays. These methods focus on 
one gene at a time but provide robust evidence of the presence of different 3' ends of 
	
Figure 1.1: 3' UTR ApA isoforms 
Recognition of the alternative pASs located in the 3' UTR generates mRNAs differing in their 3' 
UTR lengths. The mRNA isoforms created by ApA undergo different levels of regulation based on 
the regulatory sites present in their 3' UTRs. These 3' UTR ApA isoforms are translated into the 
same protein. 
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the mRNAs. Such studies established the occurrence of 3' UTR ApA where the 
recognition of the alternative pAS creates mRNAs that differ in their 3' UTR lengths 
but have the same protein coding regions (Figure 1.1).  
 
Genome-wide mapping of ApA Expressed Sequence Tags (ESTs) were the first data 
resource that enhanced the analysis of ApA from a single gene study to multiple 
sequences at the same time. Studies made use of these ESTs to show that 54% of 
genes in humans while 34% genes in mouse undergo ApA (Tian et al. 2005). To 
overcome the limitation of ESTs, microarrays with multiple probes mapping the 3' 
UTRs were used. An	early	study	used	array	analysis	to	demonstrate	that	activated	immune	 cells	 express	 shorter	 UTRs,	 suggesting	 an	 association	 between	proliferation	 an	 alternative	 ApA	 (Sandberg et al. 2008). This study also showed the 
regulation of mRNAs by ApA due the loss of microRNA binding sites from the 
extended 3' UTRs. 
 
As microarrays suffered from the limitation of pre-designed probes, next generation 
sequencing technologies brought a significant boost in identifying novel regions of the 
genome. To focus on ApA, protocols were developed to map and quantify the usage of 
3' ends of transcripts of the expressed mRNAs. Over the past few years researchers 
have progressively attempted to improve 3' end sequencing protocols so that they can 
not only be useful in identification of the 3' UTR ApA events but also provide 
quantitative usage of the cleavage sites. A number of sequencing methods for ApA 
analysis have been established so far, including 3' end RNA-seq (Yoon and Brem 
2010), PAS-seq (Shepard et al. 2011),  Poly(A)-seq (Derti et al. 2012), SAPAS (Fu et 
al. 2011), 3SEQ (Beck et al. 2010), A-seq (Martin et al. 2012), 3P-seq (Jan et al. 
2011), 3' READS (Hoque et al. 2013), and 3'-seq (Lianoglou et al. 2013). 
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Regulation of ApA in normal physiological processes Genome-wide mapping of 3' 
UTR ApA events by the various high-throughput sequencing protocols have 
established tissue and condition specific alternative 3' UTR isoform expression 
patterns. These studies confirmed that approximately 50% of human genes are 
alternative cleaved and polyadenylated while the other 50% always end at the same 
position (Shepard et al. 2011; Lianoglou et al. 2013). Several independent studies 
established the expression of ApA isoforms to be highly regulated across tissues with 
evidence of tissue-biased expression of ApA isoforms (Zhang et al. 2005; Wang et al. 
2008; Shepard et al. 2011; Derti et al. 2012; Li et al. 2012; Smibert et al. 2012; Ulitsky 
et al. 2012; Lianoglou et al. 2013). A comprehensive and systematic analysis of 3' 
UTR ApA events in ubiquitously expressed genes of diverse tissue types showed 
testes to express the shortest 3' UTR ApA isoforms with brain expressing the longest 
ApA isoforms (Lianoglou et al. 2013). This study proposed	 that	 ApA	 was	 a	mechanism	 for	 tissue-specific	 regulation	 of	 ubiquitously	 expressed	 gene. These 
patterns have also been shown to exist in flies (Smibert et al. 2012). Further it has 
been shown that the pattern of usage of pAS in a particular tissue type across species 
is more correlated that the pattern of usage of pAS across different tissue types within 
the same species (Derti et al. 2012). 
 
Multiple studies have also examined the regulation of 3' UTR ApA during 
proliferation and differentiation. Analysis of 3' UTR ApA events showed activation of 
T cells leads to creation of ApA isoforms with shortened 3' UTRs on a global level 
(Sandberg et al. 2008). There have also been studies suggesting ApA isoforms to have 
longer 3 'UTRs as the cell differentiates. Genes have been shown to have longer 3' 
UTRs during embryonic development in mouse (Ji et al. 2009). Another study with a 
focus on mouse embryonic stem (ES) cells and neural stem/progenitor (NSP) cells 
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made similar observation of expression of ApA isoforms with longer 3' UTR during 
differentiation (Shepard et al. 2011). Such observations have laid the groundwork for a 
strong association between 3' UTR ApA and cellular differentiation, which potentially 
is a layer of post-transcriptional gene regulation to achieve cellular identity. 
 
Deregulation of ApA in diseases and malignancies: Single nucleotide mutation in 
the pAS of the α2-globin gene and β-globin gene has been shown to give rise to two 
forms of rare thalassaemia leading to abnormal expression of the genes (Higgs et al. 
1983; Orkin et al. 1985). With these two cases it was long ago affirmed that a precise 
3' end of the mRNAs is essential for the efficient gene expression. Recently more 
pathological conditions associated with deregulation of 3' UTR ApA have been 
uncovered. Another such example is the FOXP3 gene where a mutation in the 
proximal pAS of FOXP3 creates mRNAs with longer 3' UTRs. This form of 
deregulation of 3'UTR ApA in FOXP3 causes IPEX, a disease with dysfunctional 
regulatory T cells followed by subsequent autoimmunity (Bennett et al. 2001). 
 
Understanding of regulation of 3' UTR ApA became even more important when 
researchers found 3'UTR ApA to be deregulated in cancer cells. It has been found that 
apart from genetic alterations, deregulated ApA could also contribute to 
tumorigenesis. Specific oncogenes have been shown to have shorter 3'UTRs in 
transformed cells compared to normal cells, aiding in production of 10 times more 
protein on average from the same amount of mRNA (Mayr and Bartel 2009). This is 
achieved by loss of repressive elements, including microRNA binding sites and AU-
rich elements, from the 3' UTR of these genes due to the widespread shortening of 3' 
UTRs. However, it is not true that deregulated ApA always increased usage of the 
shorter 3' UTR in cancer (Fu et al. 2011). While the breast cancer cell line MCF7 has 
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shortening of 3' UTRs, another breast cancer line, MB231, shows lengthening of 3' 
UTRs for majority of the genes compared to mammary epithelial cell line, MCF10A. 
This study points towards a more complex regulation of 3' UTR ApA than a simple 
shortening of 3' UTRs in cancer. Interestingly a more recent pan-cancer study across 
seven different tumor types using RNA-seq of tumor samples from TCGA consortium 
reported broad shortening of the 3' UTRs (Xia et al. 2014). They concluded that lung 
(LUSC and LUAD), uterine (UCEC), breast (BRCA) and bladder (BLCA) undergo 
the most widespread changes in 3' UTR ApA. Overall these studies have just started 
focusing on the relevance of deregulation of 3' UTR ApA isoforms in cancer. More in-
depth studies are required to discover the effects of these deregulated 3' UTR ApA 
isoform expression events in malignant cells as well as the factors responsible for 
producing these changes. As 3' UTR ApA deregulation appears to be mimicking 
genetic alterations in cancer, it opens avenues for discovering factors that could be 
targeted to make the cells have a normal 3' UTR ApA program. 
 
 
Usage of polyA sites in introns is regulated in normal developmental processes 
Approximately 20% of human genes have functional alternative pAS in the coding 
regions and introns of the transcript. Recognition of intronic polyadenylation (IpA) 
sites creates mRNA transcripts with reduced length and truncated protein product. 
Unlike the aberrant isoforms generated by the introduction of premature stop codons, 
these transcripts are not degraded by nonsense mediated decay (Lejeune and Maquat 
2005) and are stably expressed. The usage of IpA sites can result in loss of C terminal 
exons, significantly altering the function of the truncated protein product compared to 
the full-length product. In B cell maturation, the usage of the IpA site of the 
immunoglobulin antibody heavy chain gene is regulated (Early et al. 1980; Rogers et 
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al. 1980). In plasma cells, the IpA site is recognized, leading to the soluble protein 
product as opposed to its full-length product that contains a transmembrane domain in 
its C-terminus in mature B cells. This mechanism seems to be widespread as it is well 
known that intronic ApA in transmembrane proteins like receptor tyrosine kinases 
result in loss of the transmembrane anchoring domain of the protein, producing the 
soluble isoform of the protein (Vorlova et al. 2011) resulting in loss of signaling. It has 
also been shown that regulation of an IpA site can act as a developmental switch for 
the SREPF transcription factor to generate different protein isoforms in 
spermatogenesis (Wang et al. 2006). These examples show that the selective usage of 
the IpA site can potentially be a general phenomenon to regulate the protein isoforms 
with alternative C-terminal exons. Recognition of IpA sites upstream of a start codon 
can also result in loss of the open reading frame of the gene. This event can mimic 
genomic deletion as it generates a non-coding mRNA. Thus, alternative cleavage and 
polyadenylation in the introns can generate truncated mRNAs that have dramatically 
different functions. 
 
Motivated by these single gene examples, we were interested in leveraging 3'-seq, a 
next-generation sequencing method for quantifying 3' ends, to characterize intronic 
polyadenylation isoforms in normal human cells and B cell malignancies. We wanted 
to investigate if usage of IpA sites is a more widespread phenomenon that potentially 
serves as a layer of gene regulation that has not yet been appreciated. 
 
1.2 Overview of dissertation 
 
To our knowledge there has been no study that has attempted to characterize 
alternative cleavage and polyadenylation in introns on a genome-wide scale. In this 
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dissertation we characterized the landscape of intronic polyadenylation (IpA) isoforms 
across diverse normal human tissue types and B cell malignancies. Our aim was to 
study the regulation of the usage of IpA sites across diverse tissue types. We also 
investigated how the landscape of intronic cleavage events changes in malignant cells, 
which revealed a new mechanism of generating truncated mRNAs that could 
potentially mimic genetic mutations. 
 
We hypothesized that in normal tissues, IpA isoforms generated by the usage of IpA 
sites towards the 3' end of the transcription unit (Type I) would be translated into 
proteins that lack C-terminal protein domains (Figure 1.2). These IpA isoforms would 
be translated into truncated proteins that could contribute towards the diversification 
	
 
Figure 1.2: Types of IpA isoforms 
Usage of pAS located in introns generates truncated mRNAs, referred to as IpA isoforms. An IpA 
isoform created by recognition of pAS in early introns is expected to produce an mRNA that lacks 
the ability to be translated into protein. IpA isoforms generated by later pASs would be translated 
into truncated proteins. 
	 10	
of the proteome or could create a dysfunctional protein due to loss of important 
protein domains. If the IpA isoforms are generated by the recognition of the pASs 
located close to the 5' end of the gene (Type II), then those isoforms would have 
marginal probability to be translated into a protein. Such IpA isoforms could 
potentially create non-coding RNAs. In cancer, the usage of IpA sites could generate 
truncated mRNAs that could have the potential to mimic genetic mutations. The type I 
IpA isoforms could mimic loss of function mutations, frame-shift mutations, or 
genomic translocations while type II could mimic deletions (Figure 1.2).  To 
investigate our hypothesis, we first characterized the cleavage events in the introns and 
3' UTRs and then assessed the potential functional relevance of the IpA isoforms. 
 
1.2.1 Accurate mapping and quantification of the 3' ends of 
transcripts 
 
In Chapter 2 of the dissertation, I describe the different tissue and cell types that we 
analyzed. This chapter gives an overview of the high throughput method called 3'-seq, 
which is used for the detection of the 3' ends of the transcripts. It also describes the 
steps for identification and quantification of the 3' ends of the transcripts. The known 
artifacts of the sequencing protocol are also discussed. 
 
1.2.2 A comprehensive atlas of intronic and 3' UTR cleavage events 
 
In Chapter 3, I outline the steps of preparing an atlas of robustly expressed IpA and 3' 
UTR ApA isoforms. We were cautious about all the sources of artifacts that could give 
false positive peaks or events that could not be assigned to a gene with high certainty. 
Any peaks that could have originated from artifacts were discarded. We investigated 
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the possible sources that could skew the normalization for specific cell types and took 
them into account. We filtered for peaks that were robustly expressed using different 
criteria. We were able to create an atlas containing a comprehensive set of intronic and 
3' UTR cleavage events in our cell types. To ensure that the intronic cleavage events 
are real, we gathered support for the existence of those events through other sources. 
To rescue genes with convergent 3' UTRs, we learned the shape of the peaks and 
rescued some genes that could not be analyzed previously. We also describe the 
statistical framework that we used for identifying the cleavage events that are 
regulated between conditions. 
 
1.2.3 Characterization and regulation of IpA isoforms across normal 
tissue and cell types 
 
In chapter 4 we establish that IpA isoforms are expressed as part of normal expression 
program. We investigated the frequency of occurrence of IpA isoforms across normal 
tissue and cell types and whether the usage of the pASs is shared across cell types. To 
understand IpA more comprehensively, we examined where in the gene locus IpA 
occurs and the properties of genes in which it occurs. We learned that IpA is most 
frequently observed in the beginning of the transcription units. In addition, we also 
investigated the regulation of expression of IpA isoforms between conditions using a 
rigorous statistical framework. 
 
1.2.4 Deregulation of expression of IpA isoforms in B cell 
malignancies and its functional consequences 
 
We were interested in investigating how the landscape of usage of IpA sites changes 
	 12	
in malignant cells when compared to normal cells. In chapter 5, we identified the IpA 
isoforms that are differentially expressed in chronic lymphocytic leukemia (CLL) 
using 3'-seq in patient samples. We found that the genes that express IpA isoforms are 
also enriched for truncating mutations. This finding justifies our proposed hypothesis, 
as the truncated mRNAs created by the usage of IpA site could potentially mimic 
genetic mutations. We also examined the IpA isoforms of one of the frequently 
mutated genes in CLL, MGA, more rigorously to see if the mRNAs generated by 
truncating mutations and usage of IpA site share similarities. 
 
1.2.5 Functional roles of the wide-variety of mRNAs generated by 
intronic polyadenylation 
 
We hypothesized that usage of IpA site could generate a wide variety of mRNAs that 
could potentially have different functional roles. In chapter 6, we utilized RNA-seq 
data to establish that indeed the usage of IpA site located towards the 5' end of the 
transcription unit would create non-coding mRNAs. Further we showed that these 
non-coding RNAs are enriched for RNA-binding protein sites and thus potentially 
could play a role in gene regulation. We also showed that IpA isoforms generated by 
the usage of IpA sites towards the 3' end of the transcription unit would potentially 
contribute towards the diversity of the proteome. In addition, our results showed that 
only in one-third of cases does the expression of the full-length isoforms go down with 
higher expression of IpA isoforms. 
 
By our rigorous analysis of the IpA isoforms we established that expression and 
regulation of these isoforms is part of the normal expression program. Expression of 
IpA isoforms is regulated between cellular conditions and tissue types. Their 
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expression appears to be functionally relevant. We also unraveled a novel mechanism 
by which genetic mutations can be mimicked by the usage of an IpA site. We found 
expression of IpA isoforms to be deregulated in malignant cells compared to their 
normal cells. In chronic lymphocytic leukemia, these isoforms exhibit the potential to 







2. THE ACCURATE, QUANTITATIVE, AND HIGH-
THROUGHPUT MAPPING OF MRNA CLEAVAGE EVENTS IN 




Studies have shown that the cellular machinery uses alternative cleavage and 
polyadenylation in introns in important development events. In the B cell 
development, the full-length expression of the IgM gene in mature B cells switches to 
a truncated form by the usage of an IpA site in plasma cells (Early et al. 1980; Rogers 
et al. 1980). Another case exhibiting such regulation is the regulation of an IpA site  
that acts as a developmental switch for the SREPF transcription factor to generate 
different protein isoforms in spermatogenesis (Wang et al. 2006). These studies show 
that usage of IpA site can lead to alternative functional protein isoforms with 
important developmental roles. However, there has been no study that characterizes 
the global landscape, abundance and functional relevance of these isoforms across 
various tissue types. To understand the role of intronic polyadenylation (IpA) globally, 
we aimed to characterize IpA events along with 3' UTR ApA events on a genome-
wide scale in a diverse human cell types, with a focus on the B lineage cells. Our goal 
was to examine the role of IpA in generating different protein isoforms for 
maintaining normal physiological states of the cell and how changes in the IpA 
landscape result in alternative protein isoforms in B cell malignancies. In this chapter, 
we describe the tissue and cell types that we analyzed and methods for mapping and 
quantifying intronic and 3' UTR cleavage events. 
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2.2 Description of tissue and cell types being analyzed 
 
I) 3'-seq data-set 
To accomplish our objective, we needed a high throughput method that precisely 
identifies the 3' end of the mRNA and accurately quantifies usage of cleavage sites in 
introns and 3' UTRs. Lianoglou et al. (Lianoglou et al. 2013) developed a next-
generation sequencing method, 3'-seq, that identifies the 3' ends of the transcripts at 
single nucleotide resolution. This method not only accurately identifies the 3' UTR 
ApA and IpA isoforms of mRNA transcripts on a genome-wide level but also is 
quantitative at the level of ApA isoform expression. We decided to perform global 
mapping of IpA as well as 3' UTR ApA cleavage events by 3'-seq across a wide 
variety of immune cell types, primarily B cells, T cells and two B cell malignancies, 
chronic lymphocytic leukemia (CLL) and multiple myeloma (MM).  
 
We performed 3'-seq on the B lineage cell types obtained from healthy donors, as 
described below. 
 
B cell types: B cells were first isolated using a B cell kit. It was ensured that these B 
cells are CD3-and CD19 positive. Subsequently, these B cells were sorted by FACS to 
obtain specific B cell populations. The B cells were selected for the following 
markers: 
 
i. Naïve B cells (2 donors): CD38- and CD27- 
ii. Memory B cells (2 donors): CD38- and CD27+ 
iii. Germinal Center B cells (2 donors): CD38+ 
iv. CD5+ B cells (4 donors): CD5+  
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v. Plasma cells (3 donors): CD138+ 
 
All the B cells (except plasma B cells) described above were obtained from a 
lymphatic tissue (tonsils). The plasma B cells were obtained from bone marrow 
aspirates. 
 
T cells: T cells were isolated from peripheral blood using CD3 beads. These beads 
captured CD3+ T cells. It was ensured that these CD3+ T cells were CD19- (a marker 
for B cells). 
 
As we were interested in investigating the change in landscape of IpA in cancer, we 
performed 3'-seq on samples obtained from patients suffering from two different B 
cell malignancies, described below. 
 
Chronic lymphocytic leukemia (13 CLL patients): These cells were obtained from 
13 different patients suffering from chronic lymphocytic leukemia. The cells were 
isolated from peripheral blood using B-CLL Cell Isolation kit (Miltenyi). 
 
Multiple Myeloma (15 MM patients): We obtained the multiple myeloma cells from 
15 patients suffering from different stages of multiple myeloma. The cells were 
isolated from bone marrow aspirate. 
 
Apart from these cell types we also included the 3'-seq samples from Lianoglou et al. 
(Lianoglou et al. 2013). This 3'-seq dataset comprised of: human ES cell line H9, 
naïve B cells (CD27-/CD20+) from peripheral blood samples of two different healthy 
donors, testis, ovary, brain, breast and skeletal muscle. It also contains the following 
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cell lines: HEK293, HeLa, MCF10A, MCF7 and NTERA. We used all the above 
described 3'-seq samples for creating an atlas of IpA and 3' UTR ApA events. 
 
II) RNA-seq dataset	
We also performed RNA-seq for mRNA expression quantification on the above 
mentioned cell types which we utilized for different purposes in the analysis. For the 
majority of cases, RNA-seq was performed on the same samples for which we had the 
3'-seq data with some exceptions that are noted below. 
 
B cell types: 
i) CD5+ B cells (3 donors): 2 samples were the same for which we had 3'-seq 
data-set. The remaining 1 sample was obtained from the blood of a healthy 
donor. 
ii) Naïve B cells (6 donors): In this case also we had 2 samples for which we 
also performed 3'-seq. Amongst the remaining 4 samples, 1 was obtained 
from tonsil of a healthy donor and the other 3 were obtained from the 
blood. 
iii) Memory B cells (5 donors): 1 sample was the same for which 3'-seq was 
performed. The other 3 were obtained from blood and 1 was obtained from 
the tonsil of a different donor. 
iv) Germinal Center B cells (4 donors): 2 samples were common to 3'-seq 
and RNA-seq. The other 2 samples were obtained from other donors. 
v) Plasma cells (13 donors): All the samples in this case were obtained from 
different donors compared to the patients for we had the 3'-seq dataset. 




i) CLL (9 patients): For 7 patients we had the RNA-seq and 3'-seq data. 
RNA-seq for the other 2 patients was performed at a different facility. 
ii) MM (12 patients): These were same samples on which we performed 3'-
seq. We did not perform RNA-seq on samples from 3 patients for which 
we had 3'-seq data. This RNA-seq was done at the same facility as the 
plasma cells. 
 
Apart from the RNA-seq for our own samples, we also obtained RNA-seq for immune 
cells from published studies. The following samples were collected from different 
studies: 4 samples of naïve B cells from tonsil, 4 samples of germinal center B cells 
(tonsils), 2 samples of naïve B cells (blood) (ERR431624, ERR431586) (Ranzani et al. 
2015), 1 sample of CD3+ cells; GEO: GSM1576415 (Hoek et al. 2015). 
 
2.3 The 3'-seq protocol 
 
3'-seq is a high throughput tag-based sequencing protocol that aims to identify the 3' 
ends of the transcripts at single base pair resolution. The main advantage of 3'-seq is 
that apart from precise identification of cleavage events, it also provides accurate 
quantification of the IpA and 3' UTR ApA isoforms. 3'-seq uses an oligo(dT) bound to 
magnetic beads to pull down polyadenylated mRNAs and sequences the 50nt at the 
most 3' end of the mRNAs. It generates reads that align to the sense strand of the 
genes. Illumina HiSeq was used for sequencing the reads. This protocol was 
performed for all the samples as described in Lianoglou et al. to generate the 3'-seq 
dataset that forms the basis of all the analysis and results in this dissertation 
(Lianoglou et al. 2013). 
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2.4 Processing the 3'-seq data 
 
Pre-processing 3'-seq libraries The raw reads generated by 3'-seq needed pre-
processing before they could be aligned to the genome. The three main steps of pre-
processing were: 
i) Trimming low quality base pairs from the 3'-end 
ii) Trimming the 3' sequence adapters 
iii) Trimming of homopolymer As: When the oligo(dT) primed to the middle 
of the polyA tail instead of the 3' end of the transcript, then we ended up 
sequencing part of the polyA tail. These polyAs were trimmed from the 
reads. 
 
After these steps of pre-processing, the reads that were 21 nt or longer were retained 
for aligning to the genome. 
 
Alignment to the genome The pre-processed reads were aligned to the hg19 genome. 
As 3'-seq generates reads that come from the 3'-ends of the transcripts, there was little 
chance for these reads to be spliced. Thus, we used a short read aligner, Burrows-
Wheeler Aligner (bwa) for aligning the 3'-seq reads against the hg19 genome (Li and 
Durbin 2009). The final outcome of this alignment was a BAM (Binary 
Alignment/Map) file, which was used for the subsequent steps of peak calling and 
isoform expression quantification. The pre-processing and alignment was performed 
for all the 3'-seq samples to create a BAM for each sample. 
 
Peak calling of pooled samples To proceed with the subsequent analysis, rigorous 
identification of the peaks generated by read coverage of the genomic alignments was 
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required. Thus for this purpose we made use of the peak caller developed by 
Lianoglou et al. that identifies peaks by detecting edges of the genomic alignments 
(Lianoglou et al. 2013). This study suggested the pooling of all the experiments 
provides very robust detection of peaks as i) peaks are more detectable at higher depth 
of coverage and ii) batch affect are averaged out across samples. As the majority of 
cleavage sites are the same across cell types, pooling of samples aids in identification 
of the location of cleavage sites. Encouraged by this rationale we combined all the 3'-
seq samples and performed peak calling. Alignment of the reads against a genome 
provides two kinds of reads, i) reads that map uniquely to the genome and ii) reads 
that map to more than one location in the genome (multi-mapping). For quantification 
of expression levels, usage of uniquely mapping reads is widely accepted. However, 
Lianoglou et al. showed that peak calling provides the expected results if both unique 
as well as multi-mapping reads are used (Lianoglou et al. 2013). Thus, we used both 
types of reads for identification of peaks. Peak calling provided a comprehensive map 
of the genomic locations in the hg19 genome where a cleavage site was detected in at 
least one sample. These peaks were annotated with genomic context, defining whether 
a peak overlapped with either 3' UTR, extended 3' UTR (UTR3*, up to 5000 nt 
downstream of the annotated end of the 3' UTR), annotated 3' UTR of one isoform that 
is defined as intron in the other isoform (Intron.UTR3), introns, 5' UTR, extended 5' 
UTR (UTR5*, 5000 nt upstream of the annotated end of the 5' UTR), coding region 
(CDS) of a gene or non-coding genes (UTR). 3'-seq reads also map to intergenic 
regions of the genome. RefSeq annotation was used for annotation purposes. After we 
identified the location of cleavage sites, the peaks were quantified. 
 
Quantification of peaks per sample Using the universe of genomic coordinates 
where a 3' end of a transcript was detected, quantification of the expression levels of 
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IpA and 3' UTR ApA isoforms was done. Quantification was performed by counting 
the number of unique reads per sample that mapped within the region defined as a 
peak during the peak-calling step. Figure 2.4 shows the typical distribution of the 
reads mapping to different regions of the genome for a sample. Reads that spanned 
multiple peaks were assigned to the peak with the maximum overlap. The total 
number of unique reads mapped to the genome constituted the library size for the 
sample. Library size provides as estimate of the depth of sequencing for the different 
sample libraries and can be used for normalizing the expression levels of the isoforms 
by the sequencing depth. 
 
Interquartile range (IQR) of the start position of the reads 3'-seq identifies 3' ends 
at single nucleotide resolution, thus the end position of the reads mapping into the 
peak have highly similar end coordinates. However, the start position of reads always 
	
Figure 2.4: Distribution of 3'-seq unique reads mapping to different parts of 
the genes in entire genome  
Majority of 3'-seq reads map to the 3' UTR as expected. However, a fraction of reads generated by 
sequencing protocol artifacts are the internally primed (IP) and antisense reads. 
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has much higher variability for real peaks. We noticed spurious peaks that had very 
similar start position for the reads, indicating that these reads were potentially PCR 
duplicates. Thus to filter such peaks we calculated the interquartile range of the start 
position of the reads that overlapped a peak as it would give an estimate of the 
variability of the start position of the reads. In the final atlas, these spurious peaks 
were eliminated by using this IQR value. 
 
2.5 3'-seq sequencing protocol artifacts 
 
Annotation of internally primed peaks Lianoglou et al. suggested internal priming 
(IP) to be a major source of artifactual 3' ends. They pointed out that genomic region 
with A-rich stretches have a high possibility to anneal to the oligo-dTs used in 3'-seq 
followed by reverse transcription of these regions. A scenario like this would create 
peaks that would mimic internal cleavage events. These false positive peaks should be 
removed before proceeding with the downstream analysis. Thus, we followed the 
same steps as described in Lianoglou et al. to annotate these peaks as internally 
primed. These would be eventually removed from the atlas in the later steps. Figure 
2.4 shows an example of distribution of 3'-seq reads of a sample that has internally 
primed reads. 
 
Antisense reads Another source of artifactual reads was the antisense reads. 3'-seq 
generates some reads that align to the opposite strand of the gene (Figure 2.4). These 
reads were annotated as antisense reads, and there is not very clear understanding of 
the reasons that leads to sequencing of these reads. The amount of antisense reads 




3. ACCURATELY CHARACTERIZING THE LANDSCAPE OF 
ALTERNATIVE CLEAVAGE AND POLYADENYLATION IN 
HUMANS 
 
The 3'-seq data pre-processing, alignment, peak calling and quantification gave a 
comprehensive set of 3' cleavage events identified from various tissue and cell types. 
We wanted to focus only on the robustly expressed isoforms free of possible artifacts. 
We followed a series of steps to create an atlas of robust 3' cleavage events that were 
detected in the cell types being analyzed.  
 
3.1 Atlas creation 
 
To create an atlas of robust 3' cleavage events, we started with all the possible peaks 
that were detected by peak calling of all the pooled samples and then followed the 
steps below to obtain a comprehensive atlas of robust cleavage events. 
 
1. Next generation sequencing (e.g. ChIP-seq, MNase-seq, DNase-seq, FAIRE-seq) 
based functional genomics experiments often tend to produce artificial signal for 
certain regions in the genome. Certain such regions where high artificial signal 
(excessively high read mapping) has been observed repetitively across a large number 
of independent next-generation sequencing experiments have been annotated as 
“blacklisted” regions of the genome. These regions have unique mappability relative 
to the reference genome, and thus they are not removed by mappability filters. In our 
3'-seq experiments we below observed very high read mapping for these regions in 
	 24	
certain samples. We obtained an exhaustive list of these blacklisted regions 
(https://sites.google.com/site/anshulkundaje/projects/blacklists) which was compiled 
using the next-generation sequencing experiments of the ENCODE consortium 
(Consortium 2012). The peaks in these regions were removed from the atlas (n = 
3926; 0.14%). We also changed the library size of the samples by taking into account 
the number of reads of that were removed due to blacklisted peaks, as library size is 
important for sequencing depth normalization. 
 
2. As described in Section 2.5, in a 3'-seq experiment the annealing of oligo d(T) to a 
stretch of As can result in false positive cleavage events. We followed criteria similar 
to Lianoglou et al. to flag a peak as internally primed (Lianoglou et al. 2013). All the 
peaks annotated as internally primed were removed, leaving the ones that had one of 
the thirteen functional pAS in the ~10 - ~45nt upstream window (Tian et al. 2005) or 
were annotated with a known 3' end. We rescued these peaks as they have an upstream 
functional pAS, which is one of the requirements for endonucleatic cleavage by the 
cleavage machinery. This step removed 37.79% (n = 1,025,231) of the peaks from the 
atlas. As internal priming is an artifact of the sequencing protocol we reduced the 
library size of the samples by the number of reads that were lost resulting from this 
artifactual signal removal. 
 
3. Our dataset includes plasma cells, fully differentiated B cells that secrete antibodies. 
As these B cells produce massive amount of antibodies, a large fraction of 3'-seq reads 
come from parts of the genome (chromosome 2 and chromosome 14) that are 
transcribed to create the antibodies. It is important to account for this skewed 
expression of the specific genomic region for getting a reasonable expression of the 
other genes. Thus, we deleted the peaks (n = 11) overlapping with parts of the genome 
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coding for antibodies and reduced the library size of all the samples by the number of 
discarded reads. Figure 3.1.1 shows the distribution of reads before and after this 
correction. Even after this correction, two samples of plasma cells had a high number 
of intergenic reads (PC2 and PC3). Thus, we do not use these two samples for 
identification of robustly expressed isoforms but only to quantify them. 
 
4. In the next step, we removed the peaks that fell in the intergenic regions of the 
genome. As we were interested only in the 3' cleavage events of the annotated genes 
of the genome, we removed peaks that were associated with any genomic region that 
was not annotated as a coding or non-coding gene. 
 
5. To quantify the expression levels of the IpA and 3' UTR ApA isoforms, we 
determined the tags per million (TPM) of the regions that were called as peaks by our 
Figure 3.1.1: Skew in distribution of reads because of antibody production  
This plot shows the distribution of 3'-seq reads mapping to different regions of the genome across 
different samples. A large fraction of reads map to intergenic regions for the plasma cells (PC) and 
multiple myeloma (MM) samples. These regions corresponded to parts of chromosome 2 and 
chromosome 14 that code for antibodies. To account for this skewed expression of specific regions, 
we discarded such peaks.		 
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peak-caller. The read count of the peak regions was normalized by the library size of 
the respective sample. This provides an assessment of the expression level of the 
isoforms taking into account the sequencing depth coverage of the 3'-seq library for 
the individual samples. 
 
6. The genome has genes that fall on opposite strands but have convergent 3' UTRs. 
Although 3'-seq is a stranded protocol, it still suffers from artifacts of antisense reads. 
This poses problems with genes that fall on opposite strands but their 3' UTR ends are 
located within a span of 1000 nt from each other.  This is especially a problem if the 
sense and antisense peaks overlap. To have a correct assessment of the sense and 
antisense peaks, we tried to assign the peaks to the respective genes based on the 
shape and expression of the peaks. For this we made use of a supervised learning 
method that can learn the shape of the sense peaks and distinguish the real sense and 
antisense peaks for these convergent genes. The entire learning process is described in 
detail in Section 3.3. We focused on genes that had decently expressed sense and 
antisense peaks. If the learning algorithm was able to classify the peaks as sense and 
antisense, then we included the sense peak in the atlas; otherwise the peak was 
discarded. 
 
7. In the next step all the peaks that were annotated as antisense were removed 
(15.70%; n = 425,862). We reduced the library size for the samples as these antisense 
peaks were the result of sequencing protocol artifacts. 
 
8. Some genes in genome overlap with each other. In such cases, it would be difficult 
to assign the 3'-seq reads to the genes accurately. Thus we decided to remove such 
genes from analysis (n = 338). This resulted in removal of 11,489 peaks from the atlas. 
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9. The genes that were on opposite strands but have a 3' UTR end in the intron (100 
nt) of the convergent gene could create artifactual antisense peaks in the intron. Thus, 
peaks in introns that were close to the end of an opposite strand 3' UTR were also 
removed (n = 2,423). This corresponded to discarding peaks in the introns of 668 
genes. 
 
10. There are genes where the 3' UTR ends could continue in the intron of the gene 
that follows on the same strand. This would also create peaks in introns that would be 
contributed from the preceding gene. Peaks in the intron that were within 5000 nt of 
the 3' end of the 3' UTR of the previous gene were also discarded (n = 3036). Peaks 
from introns of 903 genes were removed. 
 
11. A lot of microRNAs (miRNAs) and small nucleolar RNAs (snoRNAs) are located 
in the introns of other genes. As we were interested in investigating the IpA isoforms 
of the protein coding genes, peaks originating from the 3' supervisedends of the 
miRNAs and snoRNAs located in introns would not represent real IpA isoforms. 
Thus, we decided to remove peaks in introns that were within 500 nt of an annotated 
miRNA or snoRNA. We discarded 310 peaks that were potentially 3' ends of miRNAs 
or snoRNAs from 183 genes. 
 
12. To avoid peaks that came from retrotransposons located in the introns, the peaks 
that overlapped with these retrotransposons were also removed (n = 5433, 2066 




13. A gene could have many cleavage events with adequate expression levels. 
However, we wanted to examine cleavage events that represented one of the 
substantial isoforms with respect to all the other isoforms of the genes, thus we 
decided to filter these isoforms by a usage index (UI). A usage index is a statistic that 
gives an estimate of the relative expression of the isoform. As the 3' UTR ApA 
isoforms would create the same protein irrespective of the 3' UTR length, the usage of 
the isoforms was calculated with respect to the total expression of 3' UTR ApA 
isoforms. The IpA isoforms would result into distinct proteins, thus the usage of the 
IpA isoforms was calculated relative to other IpA isoforms and 3' UTR isoforms. 
 
14. We were interested in analyzing functionally relevant isoforms, so we filtered the 
robustly expressed isoforms by using a TPM and a usage index filter. For the 3' UTR 
ApA isoforms, an isoform that was expressed with at least 3 TPM and with usage 
index of 0.1 or more was added to the atlas. To be able to focus on the more robust 
IpA isoforms we considered an IpA isoform to be robustly expressed only when it was 
expressed with 5 TPM or more and had at least 0.1 usage index in at least one sample. 
We also required the IQR of the start position of the reads to be 5 or more for the 
peaks in that particular sample to be defined as a real IpA isoform. These criteria 
helped to filter the lowly expressed isoforms as well as any possible known artifacts. 
Filtering for these expression criteria shrunk the atlas of 561,750 peaks to 48,635. 
 
15. As we were interested in IpA and 3' UTR ApA isoforms that would have different 
functional consequences, the isoforms that have the ends very close would be highly 
alike. Thus driven by this rationale, we clustered the peaks that were within 200 nt to 
represent one 3' cleavage event. As we did not want to cluster noisy events, we 
discarded cleavage events that were not robustly expressed. Clustering reduced 48,635 
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peaks to 41,605. Figure 3.1.2 shows the final distribution of the reads in a sample after 
all cleaning steps. 
 
After following the steps above, the atlas had 28,720 peaks from 15,855 genes for the 
cleavage events of the 3' UTRs. This atlas contained 3' ends of 6,465 IpA isoforms of 
4,206 genes. 
 
3.2 External validation of IpA isoforms 
 
The primary goal of this dissertation was to characterize the IpA isoforms and 
investigate the differential usage of IpA across the immune cell types and B cell 
	
Figure 3.1.2: Distribution of 3'-seq reads in the atlas 
The 3'-seq libraries were pre-processed and carefully filtered to remove all the known artifacts. 
Different criteria were used to identify robust cleavage events. After artifact removal and filtering of 
noisy events, majority of 3'-seq reads mapped to the 3' UTR as expected with a smaller fraction of 
reads mapping to other genomic loci. 	
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leukemias. Thus, it was important to have extremely confident IpA events in the atlas. 
Introns tend to be low mapability regions, so in order to avoid any IpA isoforms that 
would be artifacts, we wanted to gather additional evidence that would support the 
existence of the IpA isoforms. We tried to corroborate the existing IpA events (n = 
6465) with the sources of evidence described below: 
 
1. External annotation There are be cases where the observed IpA isoform is not 
annotated in the RefSeq database but may be annotated as 3' end in other available 
genome annotations. If IpA isoforms could be verified with these external annotations, 
which have the transcript structures from other observed data or computational 
prediction, then it would strengthen the existence of the IpA isoforms as real 3' ends. 
Thus, last exons of the all the existing transcripts of hg19 annotation for UCSC and 
ENSEMBL were obtained. These last exons were resized to get a region 50 nt 
upstream and downstream of the annotated end. If the IpA isoform 3' end detected by 
our 3'-seq analysis overlapped with this span of 100 nt, then we annotated it to be 
substantiated by an external annotation. We found that 29.06% (n = 1,879) of all the 
IpA events had an annotated 3' end in the vicinity using an external annotation. 
 
2. RNA-seq evidence RNA-seq read coverage is expected only over the exons and not 
over the introns, since the splicing machinery splices them out during co-
transcriptional processing of the pre-mRNA. However, if there is an IpA isoform that 
ends in an intron, then there should be RNA-seq read coverage before the 3' end of the 
IpA isoform and no read coverage after the 3' end (Figure 3.2.1). We leveraged this 
information from RNA-seq read coverage and identified the IpA isoforms that were 




Figure 3.2.1: Coverage of intronic regions in RNA-seq 
Higher coverage upstream of the cleavage event in the introns is expected in RNA-seq as evidemce 
of true IpA isoforms. Leveraging this knowledge, we can identify IpA events where we can observe 
higher genomic coverage upstream in RNA-seq profile compared to downstream. Using a GLM 
based model we identify the IpA events that have significantly higher coverage upstream than 
downstream of the 3' end in the introns of RNA-seq profiles. This example shows the case where a 
3' end can be validated by RNA-seq.   
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• To test whether the upstream read coverage was more than the downstream 
read coverage we created two windows of 100 nt separated by 51 nt upstream 
and downstream of the IpA 3' end.  These two windows served as replicates for 
the upstream and downstream coverage. As we did this within every RNA-seq    
sample, library size normalization was not required. Thus in this analysis the 
size factor that normalizes for the sequencing depth of the library was set as 1 
for every comparison. Now we tested if there was significant differential 
expression upstream vs downstream using DESeq (Anders and Huber 2010). If 
the IpA isoform was validated by RNA-seq then the upstream read coverage 




Figure 3.2.2: Validation of IpA events using RNA-seq  
Higher coverage is expected upstream of the cleavage event in the introns when compared to 
downstream. Windows were defined upstream and downstream (Figure 3.2.1) of the cleavage event 
and were tested for differential coverage using a statistical framework. As expected we detected 
significantly higher coverage upstream than downstream of 20% cleavage events in the introns. We 
did not observe such differential coverage when we repeated a similar analysis for windows upstream 
and downstream of random points in introns  
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• Not all IpA isoforms could be validated by this approach. To avoid cases that 
could be affected by other confounding factors, a clean list of IpA events that 
could be validated by this method was prepared. IpA isoforms where the 
defined windows overlapped with an annotated exon were excluded from the 
further analysis. An additional filter was exclusion of cases where an intron 
had more than one IpA isoform. Having multiple IpA isoforms ending in the 
same intron would be confounding. 
 
• As a control for this analysis, we chose random introns of expressed genes that 
did not contain 3' end peaks.  From the center of the intron we created 
windows upstream and downstream windows as described above. For random 
introns we should see similar coverage upstream and downstream (Figure 
3.2.2). 
 
The RNA-seq validation was applied over all the RNA-seq samples. If an IpA event 
was validated in any sample, then we considered it to be supported by RNA-seq data. 
We were able to validate 20.12% (n = 1301) IpA events with this methodology.  
 
3. Untemplated As from RNA-seq reads (polyA reads): In RNA-seq there are reads 
that come from the 3' end of the genes.  Sometimes these reads have the untemplated 
As of the polyA tail and thus fail to map to the genome. We made use of the reads that 
did not map to the human genome to get additional support for the IpA 3'ends in our 
atlas. To make sure that these reads were the 3' end reads, the reads that had 4 of more 
As at the end were trimmed. Only the reads that were greater than 21 nt in length were 
kept for further processing. Unmapped reads of all the RNA-seq samples were 
trimmed and then all the reads with untemplated As were pooled. These reads were 
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later aligned to the human genome. From the aligned BAM file, all the reads that were 
possible PCR duplicates were further filtered out.  The uniquely mappable reads 
overlapping with the IpA peak were counted. These reads supported the presence of 3' 
end from an alternative sequencing protocol, RNA-seq that is used for measuring the 
expression levels of the transcriptome. If an IpA isoform had 4 or more reads that 
supported the presence of 3' end then the IpA isoform had another source of evidence. 
This approach supported the existence of 22.72% (n = 1469) of IpA isoforms. 
 
4. Another 3' end sequencing protocol – A 3' end detected by our 3'-seq and 
observed also with another 3' end detection method would have additional confidence 
for the presence of the 3' end. This step of corroboration would make sure that the 
observed 3' end is not the result of the sequencing protocol biases as it is also being 
observed with another independent method. We found 60.97% (n = 3942) IpA 
isoforms expressed in our samples to be also expressed in atlas of 3' ends identified by 
an independent study (Derti et al. 2012). 
 
5. Presence of a polyA site (pAS) – It has been established decades ago that a 
functional pAS is critical for an efficient 3' end processing of the mRNA. The signal is 
recognized by the cleavage factors followed by the endonucleatic cleavage of the 
transcript. This hexamer signal (AAUAAA) appears 10-40 nt upstream of the cleavage 
site. Presence of this hexamer or one its variant upstream of the IpA 3' ends would 
suggest the IpA events to be resulting from real 3' ends. 89.50% (n = 5786) IpA 
isoforms were verified by a pAS signal. 
 
By the above five approaches we were able to validate 6151 IpA events of the atlas. 
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Some of these intronic 3' ends are already annotated in RefSeq. We compared the 
proportion of annotated and unannotated intronic 3' ends that could be validated by the 
above five approaches (Figure 3.2.3). Validation by RNA-seq, polyA reads and polyA 
signal were fairly similar for both the categories, which shows that the unannoated 
IpA isoforms are not resulting from artifacts. We validated fewer unannotated 
isoforms by external annotation as we were aware that most of these isoforms have not 
been annotated in any database. Even another independent protocol supported the 
presence of fewer unannotated isoforms as this data set does not include all the cell 
types present in our data set. The remaining 314 IpA events were discarded. In the 
subsequent analysis we investigated these IpA events and discarded the remaining IpA 
	
Figure 3.2.3: Validation of IpA events  
IpA events were validated using other resources. Some of the IpA events are already annotated as 
3' ends in the introns in RefSeq. We used these annotated 3' ends as baseline to assess how well the 
unannotated 3' ends could be validated by using these other resources. Similar proportions of 
annotated and unannotated cleavage events were supported by RNA-seq, polyA reads of RNA-seq 
and polyA signal. Higher numbers of annotated ends were supported by external annotation and 
other protocol. This was expected, as we knew that majority of IpA events have not been annotated 
in any database. The lack of support from other protocol was potentially because we had many 
more cell types in our dataset.  	
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events that were not corroborated any of the above methods. This gave us the final 
version of the atlas that would comprise the universe of the 3' UTR ApA and IpA 
events that would be investigated in the later analysis. 
 
3.3 Rescuing genes with convergent 3' UTRs 
 
The genome has certain genes falling on the opposite strands but having convergent 3' 
UTRs. In these cases, it is difficult to conclude whether the 3'-seq genomic read 
alignment is the outcome of expression of the gene on the sense strand or of antisense 
reads of the gene from the opposite strand. However, from examination of 3'-seq 
genomic read alignment we perceived that the shape of an authentic sense peak and 
could be learned using a supervised learning algorithm. This learning procedure could 
be used to distinguish between a true sense and antisense peak. A successful 
discrimination between an actual sense and antisense peak would help to include these 
genes with convergent 3' UTRs in our analysis. By closely examining the shape of the 
sense peaks, we realized that the shape of the peaks could be learned by using the start 
and end position of the reads overlapping with the genomic peak region. Thus we 
decided to use the start and position of the reads as features for the learning algorithm. 
We reasoned that the positive and negative cases for learning the model that could 
discriminate between the sense and antisense peaks will be the non-convergent genes 
that have a well expressed sense and a robustly expressed antisense peak. Sense and 
antisense peaks of such non-convergent genes could be used to learn the parameters of 
the model. These learned parameters could then be applied to convergent genes to 
identify real sense and antisense peaks. As retaining the start and end positions of all 
the reads mapping to the genome would have been extremely memory intensive, so we 
decided to do the learning with only few samples from the complete 3'-seq dataset. We 
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chose a diverse range of immune cell types for this purpose: GC B cells, T cells, naïve 
B cells, CD5+ B cells and two CLL samples. As described earlier, firstly the peak 
calling was performed, and then the quantification of these peaks was performed. In 
this process, apart from the number of reads that map to the peak region, we also 
saved the start and end position of all the reads mapping into a peak. 
 
Convergent and Non-Convergent Genes To proceed with the learning process we 
first needed the set of convergent and non-convergent genes. For this the raw atlas of 
peaks without any filtering was used as the starting point. The peaks possibly arising 
from artifacts were first removed by eliminating events that fell in the blacklisted 
region or were annotated as internally primed. Thereafter the peaks that mapped into 
intergenic regions of the genome or overlapping genes were removed. To get the 
expression level of the sense and antisense peaks, the TPM of the peaks was 
calculated. The genes that had convergent 3' UTRs within a distance of 1000 nt were 
called the convergent genes (n = 2,395) and the remaining genes were the non-
convergent genes. To progress with the model learning, only the genes that had a 
robustly expressed (≥  5 TPM) sense and antisense peak in any sample were used. 
 
Constructing the features for learning A learning algorithm can be used to 
distinguish between the shape of sense and antisense peaks. To do this we captured 
information about where the reads in a peak started and ended with respect to the 
annotated start and end of the peak. The following steps were used to get this 
information. 
 
i) The distance of read starts from the annotated start of the peak was 
calculated. We focused only on reads that ended within 20 nucleotides 
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upstream or downstream of the annotated start of the peak. This 
information was converted into fraction of reads starting at different 
distances from the annotated start. This created a 41 length feature vector: -
20…0…20 positions upstream and downstream of the start, where 0 
represents the start position of the annotated peak. 
 
ii) Similarly, distance of the read ends from the annotated end of the peak was 
calculated. The reads that ended within 20 nucleotides upstream or 
downstream of the annotated end of the peak were used. Again this was 
turned into fraction of reads that end at a certain distance from the 
annotated end. We observed that, for a true sense peak, the majority of 
reads end at the same position, which could be slightly different than 
annotated peak end. Thus to leverage this knowledge, the cleavage distance 
was centered at the position where the maximum number of reads ended. 
This also created a feature vector: -20…0…20, where 0 represented the 
position where the maximum number of reads ended. In this case -20 and 
20 represented the positions with the fraction of reads ending 20 nt 
upstream or downstream of the centered end.   
 
We learned the model using genes having a highly expressed sense peak as well a 
highly expressed antisense peak (≥ 5 TPM). In order to have a clean positive set for 
learning, sense peaks with at least 50% of reads ending at the same position in any 
sample (4720 peak pairs) were used. These sense peaks also had a highly expressed (≥ 
5 TPM) corresponding antisense peak, which we were aware of being an artifact. For 
these set of sense and antisense peaks we constructed the feature matrix using i) the 
fraction of reads that started within 20 nt to 20 nt downstream of the annotated start of 
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the peak and ii) the fraction of reads that ended within 20 nt to 20 nt downstream of 
the annotated end of the peak, followed by centering at the position where the 
maximum number of reads ended. The two vectors were appended to create the final 
feature matrix. This gave us a feature matrix 4720 × 82 (Figure 3.3.1). 
 
We made use of L1-regularized L2-loss support vector classification (Fan et al. 2008) 
to learn the model that could classify the sense peaks from antisense peaks for the non-
convergent genes.  The feature matrix was log transformed for the learning purpose.  
 	
 
Figure 3.3.1: Feature matrix of sense and antisense peaks for learning from 
non-convergent genes 
Feature matrix for 4720 non convergent genes (rows) with 82 columns. The first -20..0..20 represents 
the fraction of reads that end within 20 nts of the annotated end of the peak. The 0 in this case was 
centered at the position where the maximum reads ended. The next -20..0..20 shows the fraction reads 
that start within 20 nts of the annotated start of the peak, where 0 marks the annotated start of the 
peak. The differences between the two matrices for sense and antisense peaks can be seen in this 
figure. 
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The classification task was performed with an average accuracy of 88.72% by 10 fold 
cross validation. We also assessed the performance by learning the model on sense 
and antisense of peaks of 5 samples and predicting it on the 6th sample. However, our 
aim was to classify the sense and antisense peaks for convergent genes. So for this 
purpose we learned the classification model on the entire set of sense and antisense 
peaks of the non-convergent genes. We made use of the weights learnt on this 
	
Figure 3.3.2 Feature matrices of convergent genes before and after prediction 
The above two matrices (2395 ´ 82) show the feature matrices for the sense and antisense peaks for 
all the convergent genes. The weights for these features were learnt using a L1-regularized L2-loss 
support vector classification scheme. These weights were uses to classify real sense and antisense 
peaks. This helped to rescue 275 genes (shown in lower half). 
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complete dataset to classify the peaks of the convergent genes. By this procedure, we 
classified the peaks that were sense and antisense for the convergent genes. The sense 
peaks that had a positive score and their corresponding antisense peaks had a negative 
score, were the correctly classified peaks. Figure 3.3.2 shows the feature matrices of 
the sense and antisense peaks for convergent genes as well as the sense and antisense 
peaks that were predicted accurately.  We could use such genes in our further analysis. 
As our expectation was that sense peaks should be highly expressed compared to the 
antisense peaks, we included peaks that were misclassified (sense as well as the 
antisense had a positive score). Peaks that were misclassified with the above criteria, 
but had log2(count) sense peak/log2 (count) antisense peak > 0.2 were added to our 
correct classification category. This was repeated for every single sample. The peaks 
that were correctly classified in atleast 66% of samples made the final set of 
convergent genes that could be further used for the analysis. Using the learning 
strategy 275 genes with convergent 3' UTRs were added to the atlas of 3'UTR ApA 
events. 
 
3.4 Testing for differential usage of IpA sites compared to pASs in 3' 
UTRs 
 
We were interested in identifying statistically significant changes in the relative usage 
of the intronic pAS and pASs in the 3' UTR of the genes independent of the gene 
expression changes. All the full-length 3' UTR ApA isoforms would be translated into 
the same protein so we summed up the expression of all the ApA isoforms to represent 
the full length mRNAs. The IpA isoforms would be translated into a different protein 
compared to the 3' UTR ApA isoforms. If a gene has multiple IpA isoforms then we 
tested the relative expression of each IpA isoform and full-length mRNA 
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independently as each IpA isoform in translated into a different protein. To identify 
the statistically significant changes in the usage of pASs we made use of generalized 
linear model (GLM), where we model read counts of both the isoforms as negative 
binomial distribution. The model is used for testing the significance of the interaction 
between the expression of the two isoforms and the condition in which it is expressed. 
This form of modeling approach was borrowed from DEXSeq, which is formulated for 
testing the differential usage of exons (Anders et al. 2012). Lianoglou et. al. used this 
approach to test for differential usage of pASs in the 3' UTR of the genes. We used a 
similar approach, the only difference being that we tested for differential usage of IpA 





4. CHARACTERIZATION AND REGULATION OF IpA 





Previous studies have shown that the cellular machinery uses alternative cleavage and 
polyadenylation in introns in important development events. In the B cell 
development, the full-length expression of the IgM gene in mature B cells switches to 
a truncated form by usage of an intronic pAS (IpA site) in fully differentiated plasma 
cells (Early et al. 1980; Rogers et al. 1980). Another extensively studied case is the 
calcitonin/calcitonin gene-related peptide gene (CALCA), where the usage of an IpA 
site is regulated by the splicing factor SRp20 in a tissue-specific manner to make 
mRNA variants. Further, it has been shown that regulation of an IpA site can act as a 
developmental switch for the SREPF transcription factor to generate different protein 
isoforms in spermatogenesis (Wang et al. 2006). It was also demonstrated that during 
expression of FLT1, recognition of intronic polyadenylation site creates soluble 
variants of FLT1, which are highly expressed in the placenta (Thomas et al. 2007). 
These studies show that intronic polyadenylation can lead to alternative functional 
protein isoforms with important developmental roles. Usage of IpA sites was shown to 
be a widespread phenomenon using EST/genome sequence data from all the known 
human genes (Tian et al. 2007). To our knowledge no previous study that has 
attempted to characterize alternative cleavage and polyadenylation in introns on a 
genome-wide scale across a wide variety of cell types by leveraging 3'-end sequencing 
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methods. As mentioned earlier, we aimed to study the regulation of the usage of IpA 
sites across diverse tissue types that could generate protein isoforms with altered 
functions. Thus, to understand the role and extent of intronic polyadenylation globally, 
we wanted to characterize intronic alternative cleavage and polyadenylation (IpA) 
events on a genome-wide scale in a number of diverse cell types. To accomplish these 
goals we created an atlas of robust IpA events. Using this atlas of IpA events we tried 
to answer a range of questions, such as frequency of expression of IpA isoforms in 
various cell types and their preferred location within transcription units. In this chapter 
we also investigated the differential regulation of the IpA isoforms from a single a cell 
type (naïve B cells) obtained from two different environments (blood and tonsil).  This 
analysis helped us to establish that IpA isoforms are tightly regulated between cell 
types and different environments.  
 
4.1 IpA isoforms are expressed as a part of the regular expression 
program in normal cell types and display high evolutionary 
conservation  
 
Normal expression program In order to proceed with further analysis we decided to 
focus on cleavage events of coding genes. We also focused only on IpA isoforms for 
which the full-length isoform was detected in at least one of the samples. Our atlas 
constructed using a diverse range of tissue types and immune cell types identified 
5434 IpA events. We found that out of 15525 of all the expressed genes in the atlas, 
3615 genes expressed at least one IpA isoform. The atlas contained widespread usage 
of the IpA site in normal cell types. There were 1201 genes that used more than one 
intronic pAS across the transcription unit. Observing this recurrent usage of the 
intronic pAS, we concluded that recognition of these pASs by the cleavage machinery 
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was a part of the regular expression program leading to diversification of the 
transcriptome/proteome. Extensive studies have shown U1snRNP to be critical factor 
preventing the usage of the pASs in the introns causing premature cleavage and 
polyadenylation (Kaida et al. 2010; Berg et al. 2012). U1 snRNP has been shown to 
play an essential role in defining the length of mRNAs and isoform expression. These 
studies suggest that deficient levels of U1 snRNP induce premature cleavage and 
polyadenylation (PCPA) by the recognition of cryptic pASs located in the introns of 
the transcription unit (Berg et al. 2012).  However, from our observation of frequent 
occurrence of the IpA isoforms we deduced that these isoforms should not be regarded 
to be originating from cryptic pASs. Figure 4.1.1 shows the expression of IpA 
isoforms of two genes (GTF2H1 and RAB10) in different cell types. We observe a 
wide range of expression across these cell types. Our subsequent analysis showed 
usage of IpA sites to be highly regulated across multiple cell types to generate mRNA 
	
 
Figure 4.1.1: Expression of IpA isoforms across cell types 
The expression of IpA isoforms varies widely across cell types. Usage of IpA sites appear to be 




isoforms in normal physiological states of the cell.  
 
Robust expression The atlas of IpA isoforms was created to filter out transcriptional 
noise, eliminating events unlikely to produce highly expressed alternative protein 
isoforms. However, it was important to assess the robustness of expression of these 
isoforms relative to the full-length expression of the genes. The IpA isoforms were not 
as highly expressed as the full-length isoforms but their expression was high enough to 
be able to conclude that they would potentially contribute substantially to the 
diversification of the transcriptome. Figure 4.1.2 shows the expression level of the 
full-length isoforms and IpA isoforms for three cell types. The median expression 
level (log2TPM) for full-length isoforms for the PC, naïve B cells (PB) and T cells is 




Figure 4.1.2 Robust expression of IpA isoforms 
The IpA isoforms are robustly expressed in comparison to the full-length isoforms in the various cell 
types. The median expression level (log2TPM) for full-length isoforms for the PC, naïve B cells (PB) 




IpA isoforms are highly conserved compared to introns We wanted to determine if 
the 3' ends of the IpA isoforms have a different level of conservation compared to the 
other random introns. The IpA isoforms that did not have an exon upstream and 
downstream within 200 nts of the 3' end were used for further analysis (n = 4611). We 
obtained the phastCons 46-way conservation score for 200 nts up and down of the 3' 
end for these IpA isoforms (Siepel et al. 2005). We wanted to compare the mean 
conservation score around the cleavage sites of the IpA isoforms against the introns 
where IpA did not occur. For this purpose, we randomly selected introns (n = 5,000) 
of the genes that expressed IpA isoforms but did not have peak in that intron. Out of 
these random introns, we filtered for the ones that had at least one pAS (AAUAAA) in 
that intron. This would ensure that there was a chance for IpA to happen in that intron. 
After this step, one of the pAS was randomly selected and we obtained the phastCons 
		
Figure 4.1.3: Higher conservation around the cleavage site of IpA isoforms 
The mean sequence conservation upstream and downstream of the cleavage site of the IpA isoforms 
(n = 4611) is significantly higher compared to the conservation of the sequence upstream and 
downstream of randomly selected pAS (AAUAAA) from an intron that did not have the 3' end of 
any IpA isoform (One sided KS test: 1.45 x 10-170).  
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46-way conservation score for 200 nts upstream and downstream of the pAS. We 
found that the ends of IpA isoforms are significantly highly conserved (One sided KS 
test: 1.45 x 10-170) compared to these random introns at pASs (Figure 4.1.3). This 
observation suggests that IpA isoforms have been under evolutionary selective 
pressure to be expressed in different cell types and are potentially play important 
functional roles. 
 
4.2 High usage of IpA sites in immune cell types with recurrent 
sharing of the IpA sites between immune cell types 
 
Highly used IpA sites in immune cell types We evaluated a wide variety of tissue 
and immune cell types for the number of genes that express IpA isoforms. We were 
interested in determining how often IpA isoforms were expressed in different tissue 
and cell types in our atlas and if there was a biased landscape of usage of IpA sites in 
specifc cell types. We calculated the fraction of genes expressing at least one IpA 
isoform compared to all the expressed genes in each cell type. The fraction of 
expressed genes with IpA isoforms would provide an assessment of the frequency of 
the IpA isoforms in every cell type. Figure 4.2.1 shows that IpA isoforms are most 
abundantly expressed in the immune cell types with limited occurrence in the complex 
tissues. Naïve B cells (blood) had the highest fraction (0.15) of genes with IpA 
isoforms while brain had the lowest number (0.03) of IpA isoforms. The expression of 
IpA isoforms also appeared to vary between the same cell types obtained from 
different environments, as naïve B cells obtained from tonsil had lower number of 
genes (0.06) with IpA isoforms compared to naïve B cells from blood (0.13). Amongst 
the immune cell types, the fraction of genes with IpA isoforms varied from 0.05 to 
0.15, while the complex tissues ranged from 0.03 to 0.07. With this observation we 
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concluded that IpA isoforms appear to be most abundant in immune cells. This 
observation reinforces the previous claim of IpA isoforms being expressed as a part of 
normal expression program. 
 
IpA sites shared across immune cell types We wanted to find out if the cleavage 
machinery recognizes the same IpA sites across different tissue types and to determine 
if there were IpA sites that were specifically being used in a particular tissue or cell 
type. To get a global view of the tissue specificity of IpA sites we identified the IpA 
isoforms that were expressed in any tissue or cell type. Amongst these IpA isoforms 
we determined for each tissue/cell type whether the IpA isoform was expressed, the 
IpA isoform was not expressed when the gene was expressed, or if the gene itself was 
not expressed. Visualization (Figure 4.2.2) of the IpA isoforms (n = 3197) expression 
pattern shows that majority of IpA are expressed in the immune cell types and that 
these IpA sites are used in at least two immune cell types. The IpA isoforms that are 
expressed in at least 75% of the samples of a given cell type/condition were used. A 
	
Figure 4.2.1: Immune cells express higher number of IpA isoforms 
Higher proportion of expressed genes express IpA isoforms in immune cell types (0.05 to 0.15) in 
comparison to the solid tissues. Only 0.03 to 0.07 genes express IpA isoforms in the solid tissue. 
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gene is considered to be expressed if either the IpA isoform (≥ 5 TPM) or the full-
length transcript (≥ 5.5 TPM) were expressed in ¾ of the samples of the particular cell 
type. The mean expression level of the IpA isoform across all the samples had to be 
more than 5 TPM to be flagged as an expressed IpA isoform. Non-immune tissues like 
testis and ES cells express tissue-specific IpA isoforms, but the majority of these 
isoforms are expressed in tissue-specific genes, eliminating the scope for the isoform 
to be expressed in other tissue types. Presence or absence of IpA isoforms of genes 
expressed consistently across a variety of tissue types suggests the highly regulated 
usage of the IpA sites between different cell types. This pattern of expression of IpA 
isoforms also implies that these IpA isoforms might have consequential functions in 
the cell types in which they are expressed. 
 
Figure 4.2.2: Majority of IpA isoforms are shared between immune cell types 
Most of the IpA isoforms are expressed in two or more immune cell types. The tissue specific IpA 
isoforms are mostly expressed in tissue specific genes. 
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4.3 Predominant usage of promoter proximal IpA sites with increased 
recognition of promoter proximal IpA sites in cell types expressing a 
higher number of IpA isoforms 
 
The majority of IpA isoforms occur at the beginning of transcription unit The 
position of the 3' ends of the IpA isoforms in the transcription unit is extremely 
important in determining the function of the protein translated from the IpA isoform. 
If the mRNA isoforms lose fewer C-terminal exons by the usage of an IpA site, then 
the protein product would still retain most of the protein domains responsible for its 
functional activity. In such cases, the activity and functional capability of the protein 
would largely depend on the protein domains that are lost vs. retained. For example, 
loss of an active site in enzymes would make a non-functional enzyme but loss of a 
transmembrane domain from a membrane receptor would still create a soluble protein 
with an altered function. This would completely depend on the gene in question and its 
corresponding protein. By contrast, if the IpA isoforms result from recognition of IpA 
site present early in the transcription unit then these mRNA isoforms would lose most 
of the sequence that is translated into protein domains. In such cases, it would be 
highly unlikely for these IpA isoforms to create proteins that retain the original 
function. As recognition of early IpA sites would result into mRNA isoforms of 
shorter length, the probability that these mRNAs would be translated into protein 
would also go down significantly. Thus, with this insight we wanted to investigate the 
position of the 3' ends of the IpA isoforms present in our atlas. As we were interested 
in the variability of the protein translated from the IpA isoforms, we determined the 
fraction of protein coding sequence that would be retained by all the IpA isoforms of 
the atlas. We hypothesized that IpA events should occur more towards the end of the 
transcription unit, leading to loss of only few C-terminal exons in order to contribute 
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towards proteome diversity. However, we made the opposite observation (Figure 
4.3.1a) and in fact found that  more than one-third (38.64%; n = 2,100) of IpA 
isoforms in our atlas are created by the usage of pASs located in the early introns 
(with retained CDS £ 0.25) of the transcription unit. Interestingly, plenty (n = 564) of 
IpA isoforms use a pAS in the intron located upstream of the start codon, probably 
having no potential to be translated into a protein. For the remainder of the study we 
refer these early occurring/promoter proximal IpA events (with retained CDS < 0.25) 
as 5' IpA events as they occur more towards the 5' end of the transcription unit. The 
IpA events occurring towards the 3' end of the transcription unit will be referred as 3' 
IpA events (with retained CDS ³ 0.50). We describe the functional consequences of 




Figure 4.3.1 a) High usage of promoter proximal IpA sites 
The length of retained coding sequence (CDS) is the fraction of coding sequence of the original 
transcription unit that the IpA isoform has after an early termination event in the intron. A large 
fraction of IpA isoforms use the IpA site located close to the start of the transcription unit retaining 
a small fraction of coding sequence (n= 2,100 with retained CDS < 0.25);  
b) Tissues with higher fraction of genes with IpA isoforms have larger 
number of IpA isoforms ending close to the start of the transcription unit.  
The fraction of genes with IpA isoforms is negatively correlated (Pearson correlation: -0.82) with 




Higher frequency of IpA events correlated with higher incidence 5' IpA events 
We noticed that cell types with higher frequency of IpA isoforms had higher incidence 
of 5' IpA events. We wanted to see if there was a relationship between the frequency 
of IpA isoforms and location of 3' ends of the IpA isoforms across the different cell 
types. To confirm this, we calculated the median retained coding sequence (CDS) in 
nucleotides for each tissue. The fraction of genes with IpA isoforms was found to be 
strongly negatively correlated (Figure 4.3.1b; Pearson correlation: -0.82) with the 
median retained coding sequence in nucleotides across the different cell types. This 
means that if a cell type has a higher occurrence of IpA isoforms then it is likely that 
these IpA isoforms are created by the recognition of the IpA sites located early in the 




Figure 4.3.2: Diversified usage of IpA site in different tissue and cell types 
The pattern of usage of IpA site varies widely across the tissue and cell types. Ovary and brain 
have majority of IpA events towards the 3' end of the transcription unit, naïve B cells (blood), T 
cell (blood) and plasma cell have most of the events near start of the transcription unit while 
ESCs, naïve and CD5+ B cells have IpA cleavage events at both start and end of transcription 
units. 
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Diversified usage of IpA sites in wide variety of tissues and immune cell types 
Global IpA events exhibited a predominantly high usage of the IpA sites located at the 
start of the transcription unit. However, it is important to examine if this pattern of 
usage of the IpA site is consistently true across the different tissues and immune cell 
types. Thus, we examined the location of 3' ends of the IpA isoforms across all the 
tissues and cell types. Strikingly, we observed very different patterns of usage of IpA 
sites in different cell types (Figure 4.3.2). The immune cell types like the naïve B cells 
(blood) and T cells have very high occurrence of IpA events at the 5' end resulting in 
loss of the majority of protein domains while tissues like brain and breast have most of 
their IpA isoforms at the 3' end, losing very few C-terminal exons. Unlike, naïve B 
cells (blood) or brain, ES cells express IpA isoforms using both the 5' and 3' IpA sites. 
This diversification of usage of IpA sites in different tissues and immune cell types 
again points to a potential cell type specific functional role. 
 
		
Figure 4.3.3a) Tissues with shorter 3' UTRs have shorter IpA isoforms  
The tissues that have shorter 3' UTRs also express IpA isoforms shorter in length (Pearson 
correlation: 0.67). This suggests that the factors that are involved in usage of proximal pASs in the 
3' UTRs might also be involved usage of IpA sites 
b) Higher frequency of IpA isoforms associated with 3' UTR lengths 
Tissues with longer 3' UTRs have lower incidence of IpA events (Pearson correlation: -0.44). 
Tissues with longer 3' UTRs tend to have lower usage of the IpA sites. 
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Length of IpA isoforms moderately correlated with 3' UTR lengths Global trends 
of the length of 3' UTR ApA isoforms for the multi-UTR genes have been reported 
previously (Lianoglou et al. 2013). Studies have shown that brain expresses 3' UTR 
ApA isoforms with the longest 3' UTRs while testis expresses 3' UTR ApA isoforms 
with the shortest 3' UTRs, while other tissue types span the middle range (Zhang et al. 
2005; Ramskold et al. 2009; Shepard et al. 2011; Li et al. 2012; Smibert et al. 2012; 
Ulitsky et al. 2012; Lianoglou et al. 2013; Miura et al. 2013). With these established 
patterns of 3' UTR lengths for the various tissues, we wanted to address if these 
patterns held up for the IpA isoforms. More precisely, we were interested in 
determining whether the tissues that had shorter 3' UTR lengths also had IpA isoforms 
retaining less of the coding sequence. To query the relationship between the 3' UTR 
length of ApA isoforms and the position of 3' ends of IpA isoforms for the different 
cell types, we examined the correlation between these two variables. We made use of 
long usage index (LUI) for this purpose, a statistic that reflects relative abundance of 
the distal 3' UTR isoform compared to other 3' UTR isoforms. The median long usage 
index (LUI) was thought to be a fair representation for the overall 3' UTR 
lengthening/shortening of the multi-UTR genes expressed in each tissue. Thus, we 
examined the correlation between the median LUI and median retained CDS. Figure 
4.3.3a shows that there is a moderate positive correlation (Pearson correlation: 0.67) 
between shorter 3' UTRs and shorter IpA isoforms. This correlation perhaps suggests 
that protein factors playing a role in the defining the length of 3' UTRs for the genes 
on a global level might also be involved in defining the length of IpA isoforms. We 
also observed a milder negative correlation (Pearson correlation: -0.44) between 
fraction of genes with IpA isoforms and median LUI, indicating that the tissues that 
have longer 3' UTRs also have lower incidence of IpA isoforms (Figure 4.3.3b). This 
relationship could be another level of evidence hinting at the role of same machinery 
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in defining both features. 
 
4.4 Intronic polyadenylation enriched in retained introns 
 
Visualization of RNA-seq tracks along with 3'-seq tracks showed a frequent incidence 
of introns containing a 3'-seq peak to be retained in RNA-seq (Figure 4.4.1). Intron 
retention is described as form of alternative splicing where the transcribed intron is not 
spliced out during pre-mRNA processing (Black 2003). Generally, these transcripts 
with a retained intron have a premature stop codon causing them to be targeted by 
nonsense-mediated decay (NMD) pathway. The co-occurrence of IpA isoforms with 
intron retention might implicate a potential association between the two processes. As 
we had RNA-seq data for many of the same samples as our 3'-seq data, we decided to 
investigate if this pattern existed globally. We first asked if usage of IpA sites is 
enriched in introns that are retained. To examine this thoroughly we needed to 
determine the introns that are retained in the various cell types. For some of the tissues 
we did not have our own RNA-seq data, so we gathered RNA-seq data for those 
tissues from other studies (Section 2.2). For this analysis we also collected RNA-seq 
for other tissues from other studies.  We decided to identify the retained introns using 
a modified version of the IRFinder algorithm, which is also meant to detect the introns 
that are retained (Wong et al. 2013). If an intron is retained, then we should observe 
some read coverage over the intron in the RNA-seq data, and this read coverage 
should be relatively high compared to flanking exons. Thus, we took advantage of this 
knowledge and designed steps for filtering retained introns from RNA-seq data. To 
avoid genes with a complex genomic architecture we removed genes that overlap with 
other genes in either the sense of antisense strand. An intron was categorized as 
retained if it satisfied the criteria described below: 
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1) There should be at least 3 reads spanning both a) the upstream exon (E1) and 
intron junction and b) the downstream exon (E2) and intron junction. This 
criterion ensures that there were reads supporting the retention of the intron by 
making use of reads spanning the intron and the flanking exons. 
2) At least 50% of the intron length should be covered by 3 or more unique reads. 
Mappability of introns could be a limitation in this case, thus we focused only 
on introns that had at least 50% uniquely mappable sequence relative to its 
complete length. 
3) To ensure adequate expression of the flanking exons, the median coverage 
over the flanking exons was required to be 10 reads or more. 
4) Since the introns should have more coverage than the background noise, we 
considered introns to be retained if the ratio of median coverage over the intron 
	
 
Figure 4.4.1: Co-occurrence of IpA with intron retention 
Visualization of 3'-seq and RNA-seq profiles showed the pattern of occurrence of 3' end of the IpA 
isoform in retained introns. 	
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to median coverage of the upstream exon was at least 10%. A similar criterion 
was established for intron coverage relative to the downstream exon. 
 
In the next step we determined all the introns that are retained in every cell type. The 
analysis was restricted to introns of expressed genes in every cell type. An intron was 
annotated as retained if it fulfilled the above-mentioned criterias in at least 66% of the 
RNA-seq samples of the particular cell type. Introns retained in 33% or fewer samples 
were flagged as not retained while the introns that were retained in more than 33% 
samples but less than 66% of RNA-seq samples were removed from the analysis as 
nothing could be concluded about these introns. For a 3' end of an IpA isoform to 
occur in a particular intron, the intron should have a pAS that can be recognized by the 
cleavage machinery. Thus, we concentrated the remaining analysis only on the introns 
that were retained and had one of the known pASs (Tian et al. 2005).  
 
Artifacts: Our data showed that some genes had very high coverage over almost all 
the introns of the gene. This type of high coverage over all the introns appeared to be 
the outcome of sequencing artifacts. Thus to eliminate such noisy genes from the 
analysis, we removed these genes using another statistic. We determined the median 
(median coverage over all the introns)/ median (median coverage over all the exons), 
if this ratio was ≥ 0.2 then these genes were flagged for removal. A high value of this 
statistic would imply that the coverage over all the introns of the transcription unit is 
similar to or approaching the coverage level over all the exons of the transcription 
unit.  
 
If the association between intron retention and IpA existed, then the tissues with high 
IpA events should also have high intron retention cases. We observed a moderately 
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high correlation (Pearson correlation: 0.58) between the fraction of genes that had IpA 
events and the fraction of genes with intron retention (Figure 4.4.2). This observation 
motivated more analysis to demonstrate the association. As we were interested in 
determining if 3' ends of IpA were enriched in retained introns, we first determined the 
number of introns that are retained and also have a 3' end of an IpA isoform in the 
particular intron just by random chance. Then we determined the actual number of 
introns that had the 3' end of an IpA isoform and are retained. We found the co-
occurrence of IpA with intron retention was more frequent than just by random 
expectation (Figure 4.4.3a). The association between the two processes was 
authenticated by statistical enrichment (Fisher’s exact test), showing IpA to be 
enriched in introns that are retained (Figure 4.4.3b).  
		
Figure 4.4.2: Association between intron retention and occurrence of IpA  
Tissues with higher number of genes with intron retention also have more genes that express IpA 
isoforms (Pearson correlation: 0.58). This observation suggests of a possibility an association 
between the two phenomenon.  	
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Co-occurrence of intron retention and IpA isoforms in the same introns suggests an 
association between the two phenomena. We hypothesized that retention of intron 
(inclusion of the intron in the transcript) could be a requirement for IpA to occur in 
these introns; however it is difficult to establish the direction of causality with the 
available data and would need experimental work to make strong conclusions. We 
found that the median usage of the IpA isoforms that co-occurred with intron retention 
is lower compared to IpA isoforms in introns that are not retained (Figure 4.4.4). This 
observation suggests perhaps we could not detect intron retention in these highly used 




Figure 4.4.3 a) Higher incidence of IpA events in introns with IR (intron 
retention) 
The number of introns where IpA and IR is observed simultaneously is much higher than expected 
by chance;  
b) Significant enrichment of IpA in retained introns 
Motivated by the observation made in 4.4.3a we found that IpA events are significantly enriched in 
introns that are retained in contrast to introns that are not retained. This establishes an association 
between IR and IpA. However, it is difficult to establish the causality of the events. We 
hypothesize that cleavage machinery recognizes the IpA sites in the retained introns causing the 
formation of 3' end. 
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4.5 Enriched pASs, depleted U1 snRNP, long introns and long 
transcription units define the landscape of the genes with IpA 
isoforms 
 
Having observed a widespread usage of IpA sites in the expressed genes, we wanted to 
determine if the genes exhibiting these isoforms had any special features that make 
them different from the genes that always express full-length isoforms. We 
investigated the differences in the sequence signals and the genomic architecture 
between the genes that express IpA isoforms and the genes that only express full-
length 3' UTRs.  
 





Figure 4.4.4: IpA events with lower usage index co-occur with intron retention 
The median usage of the IpA isoforms that co-occurred with intron retention is lower compared to 
the introns that are not retained. This observation suggests that it could be possible that we could not 
detect intron retention in these highly used IpA isoforms as 3' end cleavage was highly efficient, 
leaving no reads after the cleavage event. 
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50% of the genes always have single UTRs while the remaining 50% undergo 3' UTR 
ApA and thus are referred as multi-UTR genes (Shepard et al. 2011; Lianoglou et al. 
2013). We were interested in determining if the genes that expressed IpA isoforms 
were enriched in either of these two categories. We found that 30% of the multi-UTR 
genes express IpA isoforms while only 17% of the single UTR genes express IpA 
isoforms. Our results showed that genes with IpA isoforms are significantly enriched 
(Fisher’s exact test: p < 2.69 ´ 10-82) amongst the multi-UTR genes compared to 
single UTR genes. This enrichment elucidates a tighter regulation of expression of the 
single UTR genes with multi-UTR genes having the genomic landscape to provide 
additional layers of regulation via IpA and 3' UTR ApA isoforms. 
 
IpA isoforms occur in transcription units enriched for pASs and depleted for U1 
snRNP signals Presence of a functional pAS has been shown to be essential for the 
efficient 3' end processing and cleavage of the transcript (Proudfoot 2011).  As 
formation of the 3' ends of the IpA isoforms would also require pASs, it is important 
to investigate the sequence context of the genes with IpA isoforms to unravel what 
makes them different from the genes that only express full-length 3' UTRs. Another 
factor that potentially plays a crucial role in the creation of the IpA isoforms is a small 
nuclear ribonucleoprotein, U1 snRNP. U1 snRNPs have been shown to play an 
essential role in preventing the premature cleavage and polyadenylation (PCPA) 
during pre-mRNA processing (Kaida et al. 2010). Deficiency of U1 snRNP leads to 
PCPA (premature cleavage and polyadenylation) and creation of mRNA isoforms of 
varied lengths (Berg et al. 2012).  U1 snRNP binds to hexamer sequence signals 
(GGUAAG, GGUGAG, GUGAGU) and prevents the recognition of the pASs in the 
vicinity (Mount et al. 1983). Further it has been shown that the appropriate direction 
of transcription is maintained by the enrichment of U1 snRNP signals and depletion of 
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pASs in the promoter proximal region of the transcription unit (Almada et al. 2013). 
Thus, we wanted to assess the frequency of the pAS and U1 snRNP in transcription 
units with IpA isoforms. We only looked for the top two most used pASs (AAUAAA, 
AUUAAA) (Tian et al. 2005) to avoid accounting for very pervasive pASs that are not 
very functionally efficient. Indeed, we found the occurrence of pASs to be higher (one 
sided KS test, p < 5.49 ´ 10-53) in the gene bodies of genes that express IpA isoforms 
(n = 3671) compared to genes that only express full-length 3' UTRs (n = 11775) 
(Figure 4.5.1a). Additionally, genes with IpA isoforms are also depleted (one-sided 
KS test: p < 3.97 ´ 10-40) for the U1 snRNP sequence signals in comparison to genes 
that always express full-length 3' UTRs (Figure 4.5.1b). This enrichment of pASs and 
depletion of U1 snRNP binding sequences may provide an adequate landscape for the 
creation of the IpA isoforms in these transcription units. 		
	
 
Figure 4.5.1: Genes with IpA isoforms enriched for pASs and depleted for U1 
snRNP sites 
Expression of IpA isoforms is facilitated by the sequence composition of the genes. The genes with 
IpA cleavage events are enriched for pASs (one sided KS test, p < 5.49 ´ 10-53), that is recognized by 
the cleavage machinery for 3' end processing. These genes are also depleted (one KS test, p < 3.97 ´ 
10-40)  for U1 snRNP signals where U1 snRNPs bind to prevent premature cleavage events. The 
presence of pASs and absence of U1 snRNP signals makes these genes suitable candidates for 
expression IpA isoforms. Sequence composition of the IpA genes (n = 3671) was compared to the 
genes that always express full-length isoforms (n = 11775).  
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Longer introns and longer transcription units aid the creation of IpA isoforms 
Apart from the sequence context of the genes with IpA isoforms we were also 
interested in the structural differences between transcription units that do or do not 
express IpA isoforms. These features could help us to determine the factors that aid 
the creation of IpA isoforms. As our previous results showed that IpA events are 
enriched at the start of transcription units (5' IpA events), we also wanted to examine 
the differences in the genomic architecture of the 5' and 3' IpA events. To have a clean 
signal we used the following definition for the 5' and 3' IpA events: 5' (fraction of 
retained CDS in nt < 0.25) and three-prime (0.50 < fraction of retained CDS in nt < 
1.0). We compared the width of the introns, width of the transcription units and width 
of the 5' UTRs. IpA isoforms occur in significantly longer transcription units (one 
sided KS test: p ~ 0) with wider 5' UTRs (one-sided KS test: p < 4.93 ´ 10-29) when 
compared to genes that only express full-length 3'-UTRs (Figure 4.5.2), which is 
consistent with a previously reported observation (Tian et al. 2007). When a similar 
comparison was performed between the 5' and 3' IpA events, we found 5' IpA events 
tend to occur in longer introns, longer transcription units and longer 5' UTRs (one-
sided KS test, p < 9.59 ´ 10-66; p < 9.68 ´ 10-08;  p < 1.39 ´ 10-09, respectively; Figure 
4.5.2). This suggests that large intron size and long transcription units could be a 
determining factor for the usage of the IpA site leading to the formation of the IpA 
isoforms. The 5' IpA events also tend to occur in significantly longer 5' UTRs, with 
many of them having an intron in the 5' UTR, providing an opportunity for formation 




4.6 Expression of IpA isoforms is differentially regulated between 
different cellular conditions 
 
So far we focused our analysis on the characterization of the IpA isoforms across the 
wide variety of tissue and immune cell types. We also tried to distinguish the genomic 
features that aid in the formation of the IpA isoforms. Having answered these 
questions, we wanted to determine how significantly different the IpA isoform 
expression levels were for naïve B cells obtained from two different environments of 
the healthy donors – blood and tonsils. We used a generalized linear model (GLM) as 
described earlier (Section 3.3) to determine if there was a differential usage of the IpA 
sites when compared to full-length 3' UTR isoform (Anders et al. 2012; Lianoglou et 
al. 2013). This form of GLM adjusts for the differences in the sequencing depth of the 




Figure 4.5.2: Occurrence of IpA isoforms in genes with long transcription 
units, long introns and wider 5' UTRs 
5' IpA events tend to occur in long introns. Genes that have IpA isoforms have longer transcription 
units and wider 5' UTRs compared to genes that only express full-length 3' UTRs. The genes 
expressing IpA isoforms have these special characteristics that are different from the genes that only 
express full-length isoforms. This suggests that large intron size and long transcription units could 
be a determining factor for the usage of the IpA site leading to the formation of the IpA isoforms. 
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condition. It allows for testing for significant differences for relative expression of IpA 
isoform and full-length isoform after accounting for the differences in the gene 
expression in the different conditions. Using this GLM model we compared two 
independent samples of naïve B cells (blood) against the naïve B cells (tonsils). An 
IpA isoform goes into the analysis only if either the full-length is expressed (> 5.5 
TPM) or IpA isoform is expressed (> 5 TPM) in 75% of normal B cells or any of the 
cancer samples (IpA = 1,164). The IpA sites with a usage difference between the two 
cell types was more than 10% with adjusted p < 0.1 were considered to be 
significantly different between the conditions (n = 364, high usage = 331, loss of 
usage = 33 in naïve B cells (blood), Figure 4.6.2). This comparison revealed that in 
majority of the cases there is an increase in the usage of IpA sites of naïve B cells 
(blood) with fewer cases where there is an increased usage of IpA sites of naïve B 
cells (tonsils). We found that this switch in isoform expression potentially contributes 
towards cellular phenotype. An example that supports this idea is the spectrin 
(SPTBN1) gene which has a significantly higher usage of the IpA site in blood B cells 
(Figure 4.6.1). Spectrin plays an important role in defining the cell shape along with 
the arrangement of transmembrane proteins and organization of organelles. This actin 
crosslinking and molecular scaffold protein that links the plasma membrane to the 
actin cytoskeleton has a Pleckstrin homology domain (PH domain) (Das et al. 2008). It 
has been shown that the PH domain is critical for the localization of the protein on the 
plasma membrane. The naive B cells in the tissue environment (tonsils) would need 
spectrin on its plasma membrane for the maintenance of cell shape and tissue 
structure. However, the naïve Bcells in the blood environment do not need to maintain 
the tissue structure and thus do not need the spectrin protein on its plasma membrane. 
This explains the high expression of the IpA isoform that lacks the PH domain in 
naïve B cells obtained from blood. More detailed screening of the list of the genes that 
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significantly change their isoform usage might reveal more candidate genes are 
directly involved in cellular functioning. These results demonstrate tight regulation of 
IpA isoforms between cell types and environmental conditions. They also suggest that 
these significantly regulated IpA isoforms are potentially functionally relevant. These 
observations clearly indicate that expression of IpA isoforms should not be viewed as 
usage of cryptic IpA sites or as premature cleavage polyadenylation induced by the 





Figure 4.6.1: IpA isoform is expressed in Naïve B cells obtained from blood 
Spectrin expresses an IpA isoform in naïve B cells obtained from blood. This isoform is absent in 
the naïve B cells that are obtained from tonsils. The expression of this IpA isoform is regulated 
between the different cellular environments suggesting of a functional consequence between the 
conditions. The IpA isoform lost the PH domain that is required for the transport of SPTBN1 to the 




Figure 4.6.2: Significantly differently used IpA sites between naïve B cells 
from blood and tonsils (N = 364) 
The usage of IpA sites is regulated between cellular conditions. Naïve B cells from blood have 
significantly higher usage of IpA sites compared to naïve B cells obtained from tonsils (n = 331). 





5. DEREGULATED IpA ISOFORMS EXPRESSION IN 
LEUKEMIAS 
 
Cancer is largely associated with genetic abnormalities that include mutations, 
chromosomal translocations, deletions and amplifications. These genetic abnormalities 
in proto-oncogenes are considered to be drivers that lead to malignant cells with 
uncontrollable growth. In many cases, overexpression of oncogenes is also observed 
without any genetic alteration. Shortening of the 3' UTR by ApA has been shown to 
contribute to tumorigenesis by increased production of protein from the same amount 
of mRNA (Mayr and Bartel 2009). Studies have observed deregulated 3' UTRs in 
cancers, with a shift towards shortening of 3' UTRs across a wide variety of cancers 
with some exceptions (Fu et al. 2011; Morris et al. 2012; Xia et al. 2014). All the 
studies so far have focused on the shift in patterns of length of 3' UTRs. There has 
been no study that has characterized the changes in the landscape of usage of IpA sites 
in cancer. Thus we wanted to investigate the changes in relative expression of IpA 
isoforms vs. full-length isoforms for B cell derived malignancies compared to normal 
B cells. As discussed earlier, we hypothesize that a relatively higher usage of IpA sites 
would create truncated mRNAs that could have the potential to mimic genetic 
alterations, like mutations, deletion, and chromosomal translocations. Generating an 
IpA isoform could be an alternate way for the cancer cell to have similar effects as the 
genetic alterations. To investigate this hypothesis, we performed the following 
analysis. 
 
We were interested in examining the extent of differential expression of IpA isoforms 
	 70	
compared to full-length isoform in chronic lymphocytic leukemia (CLL) and multiple 
myeloma (MM). CLL is the leukemia of naïve/CD5+ B cells that normally occurs in 
adults. MM is a cancer formed by malignant plasma cells, which is very aggressive 
with very low survival rate. We compared each of these leukemias to their respective 
normal cell types and identified the significant changes in the relative usage of the IpA 
site and full-length 3' UTR pAS. 
 
5.1 Truncated mRNAs generated by usage of IpA site can potentially 
mimic genetic mutations 
 
Higher usage of IpA sites in CLLs: We were interested in identifying statistically 
significant changes in the relative usage of the IpA sites and pASs in the 3' UTR of 
genes independent of gene expression changes between CLL samples and naïve/CD5+ 
B cells. We had CLL samples from 13 patients and 6 naïve/CD5+ B cells from healthy 
donors. Before testing for statistically significant changes, we wanted to determine 
whether all the CLL patients could be treated as one single condition or whether they 
should be classified into separate groups. Thus we performed hierarchical clustering of 
the CLL samples using their IpA expression levels (TPM). This helped us to define 
three separate groups of CLL patients (group 1, 3 patients; group 2, 5 patients; and 
group 3, 5 patients). Each group of CLL patients was compared against the normal B 
cells (which we call “group-wise” comparisons). As described earlier, an IpA isoform 
goes into the analysis only if either the full-length isoform is expressed (> 5.5 TPM) or 
the IpA isoform is expressed (> 5 TPM) in 75% of normal B cells or any of the cancer 
samples (IpA isoforms = 1,840; genes = 1,406). These genes were then tested for 
differences in relative usage of the IpA sites or pASs in the 3' UTR. We also repeated 
this analysis in a slightly different manner, where we compared every single sample 
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against all normal B cells (we call these “sample-wise” comparisons). In the group-
wise comparison, we found that two of the groups (group 2 and group 3) of patients 
had fewer changes compared to normal B cells in the usage of the IpA sites compared 
to full-length while one group (group 1) showed significantly higher usage in CLL 
patients (adjusted p < 0.1; usage difference > 0.1). 345 IpA isoforms showed higher 
usage of the IpA site in at least one the defined CLL groups while there were only 75 
IpA isoforms with lower usage of the IpA site. To select more robustly changing IpA 
events, an additional criterion of usage fold change between case and control (Usage 
index FC > 3) was used (Figure 5.1.1a). 171 IpA isoforms have increased usage of the 
IpA site while 19 IpA isoforms show loss of recognition of IpA site with the added 
criterion. We identified the IpA isoforms that are most recurrently highly expressed 
across at least one quarter of the CLL patients (n >= 4) using the sample-wise 
comparisons. Figure 5.1.1b shows the usage index of these IpA isoforms across the 
different CLL and naïve/CD5+ B cell samples.  
 
Enrichment for truncating mutations: We had hypothesized that usage of IpA sites 
could have the potential to mimic genetic alterations. The truncated mRNAs that lose 
their ability to be translated into proteins would be phenocopy genomic deletions or 
nonsense mutations. IpA isoforms loosing C-terminal exons could potentially mimic 
loss-of-function mutations, frame-shift mutations or chromosomal translocations. To 
investigate this hypothesis, we collected information about genes that are mutated in 
CLL patients from the available studies (Puente et al. 2011; Quesada et al. 2012; 
Landau et al. 2015). Since IpA isoforms would certainly be translated into different 
protein sequences than those obtained from full-length isoforms, we focused on 
truncating mutations (nonsense mutations, frame-shift mutations and splice-site 
mutations) in expressed genes that would likely have a similar outcome as IpA 
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isoforms. We found 637 expressed genes to harbor one these mutations in CLL 
patients. Amongst the 330 genes that have significantly higher usage of an IpA site, 34 
genes were also found to have one the truncating mutations. In support of our 
hypothesis we found that genes with high usage of IpA sites are significantly enriched 
		
Figure 5.1.1a) High usage of IpA site in CLLs compared to naïve/CD5+ cells: 
171 IpA isoforms are more highly expressed in CLL while for only 19 IpA isoforms there is 
decreased usage of IpA site (adjusted p < 0.1, usage index difference < 0.1 and usage fold change > 
3);  
b) Recurrently highly used IpA sites in CLL samples 
26 IpA site are significantly highly used in at least one quarter of CLL samples in sample-wise 
comparison relative to pAS in 3' UTR. 
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for truncating mutations (Fisher’s exact test, p < 0.04). It was important to assess if the 
mutation occurs before or after the 3' end of the IpA isoform. If the mutation occurs 
after the 3' end of the IpA isoform, then there would be higher potential for the IpA 
isoform to have comparable functional consequences as the mutated isoform. Figure 
5.1.2 shows the sequence that is retained by the IpA isoform and the position of the 
mutations along the gene length. In most of the cases we observe that the mutation 
occurs after 3' end of the IpA isoform, suggesting that IpA isoforms might have 
comparable functional effects as the genetic mutations. This observation also points 
towards the possibility for the malignant cell to use IpA in order to achieve similar 
functional consequences contributing towards tumorigenesis without presence of any 
genetic alteration. 
 
We also wanted to compare the proportion of CLL patients with increased usage of 
IpA site with the proportion of patients that harbor truncating mutations in these 34 
genes. We also included available copy number variation data for this purpose (Pfeifer 
et al. 2007). Strikingly, we found that higher usage of the IpA site occurs in a much 
higher proportion of patients compared to patients with mutations (Figure 5.1.2). This 
observation further supports the hypothesis that disruption of IpA could be an 
alternative way for the cancer cell to phenocopy somatic mutations. 
 
MGA IpA isoform is similar to mutated isoforms Amongst the 34 IpA genes that 
are mutated in CLL patients, we found MGA to be most recurrently mutated in CLL 
patients. The MGA IpA isoform is robustly expressed in CLL patients (Figure 5.1.3). 
Mga is a transcription factor that is famously known as a dimerization partner for 
Max. Mga has been shown repress Myc’s oncogenic transcriptional activity by 
occupying the promoters of Myc’s target genes along with Max.  Studies have also 
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shown that the presence of Mga reduces Myc-induced oncogenic transformation  
(Hurlin et al. 1999). This finding suggests that loss of functional MGA via a truncating 
mutation would enhance Myc-induced oncogenic transformation in cancer cells. 
		
Figure 5.1.2: Truncating mutations enriched in genes with highly used IpA 
site in CLLs 
The genes with high usage of IpA sites are enriched for truncating mutations (Fisher’s exact test; p 
< 0.04). In the majority of cases we observe truncating mutations to occur after the 3' end of the 
IpA isoform, suggesting that high usage of IpA site leads to loss of the same or more exons as the 
mutation. Higher usage of the IpA site occurs more frequently across CLL patients compared to the 
occurrence of corresponding mutation in CLL patients. This suggests that usage of IpA sites may 
be an alternative way adopted by cancer cells to phenocopy the effect of genetic mutations.  	
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Figure 5.1.2 shows that the majority of the truncating mutations of MGA occur after 
the 3' end of the IpA isoform, indicating that the IpA isoform would lose same or a 
greater number of C-terminal exons as the mutated isoform. Only 2% of patients had a 
truncating mutation in MGA while 15% of patients exhibited high usage of the IpA 
site in MGA. This observation again suggests that the malignant cells potentially have 
adopted an alternative way of disrupting Mga expression to enhance Myc-incduced 
transformation without any genomic mutation. 
 
 
5.2 Widespread usage of distal pAS in 3' UTRs 
 
As we observed increased usage of IpA site in CLLs, we wanted to investigate if there 
was a global pattern of shift towards generating shorter mRNAs in CLL. Global 
shortening of 3' UTRs has been reported in other cancer studies (Mayr and Bartel 
	
		
Figure 5.1.3: Robustly expressed IpA isoform of MGA 
MGA is recurrently mutated in CLL patients. The usage of an IpA site in MGA increases 
significantly in CLL patients. The IpA isoform appears to result in a truncated protein similar to the 
mutated isoform. This suggests that expression of IpA isoform could be an alternative way CLL 
cells to enhance Myc-induced transformation in the absence of an MGA genetic mutation. 
	 76	
2009; Morris et al. 2012; Xia et al. 2014). For this analysis we focused on determining 
if there was a significant difference in the relative usage of the alternative pASs in the 
3' UTR between the CLL groups and naïve/CD5+ B cells. We used the GLM based 
approach as described in Lianoglou et al. Only the genes that were expressed (> 5.5 
TPM) in every sample went into the analysis (n = 3449). As B cells express multiple 
ApA isoforms, we decided to test the two most variable alternative pASs between the 
samples. In contrast to our expectations, we found that there is a global shift towards 
longer 3' UTRs in CLL (adjusted p < 0.1, usage difference > 0.1, longer 3' UTRs = 
878, shorter 3' UTRs = 347). Figure 5.2.1 shows a heatmap with global changes in the 
usage of the alternative pASs in the 3' UTR. A majority of ApA studies have reported 
a shift towards usage of shorter 3' UTRs in cancer. However, in CLL cells, ApA 
appears to be disrupted to create longer 3' UTRs. Theresome, in CLL, the cleavage 
and polyadenylation process is deregulated in a manner such that, on one hand 
truncated IpA isoforms are created while on the other hand genes express mRNAs 
with longer 3' UTRs. CLL cells potentially could be using both forms of deregulation 
for their survival and growth. 
 
5.3 Loss of usage of IpA sites in multiple myeloma 
 
We also examined the change in landscape of usage of IpA sites in multiple myeloma 
cells compared to plasma cells. We performed to 3'-seq on 15 samples obtained from 
multiple myeloma patients and 2 samples of plasma cells from healthy donors. As the 
samples were obtained from patients at different stages of multiple myeloma, we 
wanted to define groups of patients that were most similar to each other. Using 
hierarchical clustering based on the expression of the 50% most variable IpA isoforms, 
patients were divided into three groups (group 1, group 2, and group 3). We carried 
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out the GLM modeling  as described above to determine the differential usage of IpA 
sites compared to pASs generating full-length isoforms for these three MM groups 
compared to normal plasma cells. In contrast to CLLs, we found that two groups of 
MM patients showed loss of usage of IpA sites compared to plasma cells. Out of the 
1118 IpA isoforms that were analyzed (adjusted p < 0.1, difference in usage index < 
		
Figure 5.2.1: Longer 3' UTRs in CLLs 
CLLs show higher usage of the distal pAS in the 3' UTR compared to the normal naïve/CD5+ B 
cells (longer 3' UTR, 878 genes; shorter 3' UTRs, 347 genes). The figure shows the difference in 
the long usage index of CLLs and mean long usage index of normal B cells. This is in contrast to 
the widespread shortening observed in cancer cells in many studies. 
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0.1), 356 IpA sites have loss of usage of an IpA site while 10 IpA isoforms show 
increased usage of an IpA site in MM. Figure 5.3.1a shows the mean usage index of 
IpA sites in the three MM groups and plasma cells. This loss of usage of IpA sites also 
affects important genes in MM biology, like the transcription factor IKZF1 (Figure 
5.3.1b).  These results show that deregulated cleavage and polyadenylation process 
does not result in similar global shifts in different malignancies. 
		 	
		
Figure 5.3.1a) Loss of usage of IpA sites in multiple myeloma cells 
In contrast to CLL we observe loss of usage of IpA sites in multiple myeloma compared to plasma 
cells (adjusted p < 0.1, difference in usage index < 0.1, loss of usage of IpA sites: 356, high usage of 
IpA sites: 10); b) IKZF1, an important transcription factor in MM biology shows loss of usage of IpA 




6. INTRONIC POLYADENYLATION CREATES A POOL OF 
mRNAS WITH A WIDE VARIETY OF FUNCTIONS 
 
IpA isoforms generated by the usage of IpA sites could have the potential to play a 
variety of functional roles. Their robust expression and cell type specific regulation 
suggest that alternative IpA isoforms may have different biological functions. 
Demonstrating the role of every IpA isoform would require a comprehensive set of 
experiments establishing the precise function of the isoform. We attempted to get an 
overall view of the potential functions of the mRNAs generated by the usage of IpA 
sites through computational analysis. 
 
6.1 5' IpA events create non-coding RNAs with a potential role in 
gene regulation 
 
5' IpA isoforms are likely non-coding We found (Figure 4.3.1a) that a large fraction 
of IpA isoforms have 3' ends near the start of the transcription units. Positional 
analysis showed enrichment for the usage of the IpA site located close to the 5' end of 
the transcription unit (5' IpA isoforms). All these 5' IpA events create IpA isoforms 
that retain 0 or < 0.25 of protein coding sequence. We hypothesized that such 5' IpA 
isoforms would have limited potential to be translated into a protein and thus would 
probably be non-coding RNAs. Previous studies have created RNA maps where they 
observe a similar class of short RNAs resulting from pervasive transcription 
(Kapranov et al. 2007). Recently there have been a number of studies showing the role 
of promoter proximal non-coding RNAs in cis-regulation of the genes. For example, a 
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non-coding RNA generated from the minor promoter of dihydrofolate reductase 
(DHFR) has been shown to repress the transcription of the gene (Martianov et al. 
2007). The non-coding RNA interacts with the major promoter causing promoter-
specific transcriptional repression of DHFR. Another study demonstrated the role of a 
novel RNA in regulation of CEBPA, a transcription factor involved in the 
differentiation of immune cells (Di Ruscio et al. 2013). This RNA is transcribed from 
the CEBPA gene locus and plays an essential role in regulating the local DNA 
methylation profile. It was shown that this RNA binds to DNMT1, a DNA 
methyltransferase preventing CEBPA gene locus methylation. In another example, 
promoter associated RNAs have been shown to mediate transcriptional repression by 
some form of interaction with the promoter region of the gene (Han et al. 2007; 
Schmitz et al. 2010). Motivated by these examples we wanted to determine if the 5' 
IpA isoforms would also form a set of non-coding RNAs that might have the potential 
to mediate gene regulation. To investigate this hypothesis the complete transcript 
structure with the 3' end of the IpA of the isoform was required. Having the complete 
transcript structure would enable prediction about the coding potential of the 
transcript. Thus for this purpose we utilized RNA-seq data and performed de novo 
transcript assembly. 3'-seq data was used for precisely defining the 3' end of the 
transcripts. 
 
De-novo transcript assembly As the majority of IpA isoforms in our atlas are present 
in immune cells, we decided to use a compendium of immune cell RNA-seq data, 
generated by us as well as gathered through other resources, for our analysis. During 
our intron retention analysis we observed that certain RNA-seq libraries had very high 
coverage in introns relatively to flanking exons. These samples were excluded in order 
to avoid assembly of transcripts with spurious structures. The complete transcript 
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structure was obtained by following steps: 
 
1. We used STRINGTIE, a novel and improved method for more accurate de 
novo assembly of the transcripts (Pertea et al. 2015). The de novo assembly 
was performed on every RNA-seq sample with default settings using hg19 
RefSeq annotation (obtained from UCSC). 
2. These transcripts from the multiple assemblies were subsequently unified using 
Cuffcompare, which removes all the redundant transcripts (Trapnell et al. 
2012). It provides a set of unique transcript structures after combining all the 
assemblies. 
3. For every single gene, we obtained the transcripts that overlapped the gene 
coordinates. We preferred multi-exonic transcripts to single exon transcripts. 
For the single exon transcripts we allowed the start/end to be within 100 nt of 
the TSS (Transcription Start Site). We gave this advantage to the single exonic 
transcripts because the direction of the transcription for these transcripts is not 
certain. 
4. Now using the 3' ends of IpA isoforms (from our 3'-seq data), we assigned 
transcripts with nearest ends to these IpA isoforms. Firstly, we identified 
transcripts that ended within 50 nucleotides of the 3' ends. If there were several 
assembled transcripts that ended within 50 nucleotides of the 3' end then we 
chose the transcript that had the maximum number of exons. If there was a tie 
in the number of exons then we chose transcripts that started closest to 
annotated TSS. For the remaining 3' ends, we assigned the nearest ending 
transcript. 
 
Finally, using the above defined criteria for selecting the transcript structures, we 
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determined which IpA isoforms corresponded to these assembled transcripts. If the 3' 
end of the IpA isoform was within 500 nt of the defined transcript end, then we 
assumed that this particular transcript represents the full structure of the transcript that 
ended there. For some IpA isoforms we observed usage of alternative pASs within the 
introns. Thus to account for such cases, for the 3' ends of the IpA isoforms that did not 
have a transcript end within 500 nt, we determined if it overlapped a transcript that 
ended within 5000 nt. If this was the case, then we assigned this transcript to that 3' 
end. We were able to define the transcript architecture for n = 3202 3' ends of the IpA 
isoforms (annotated and unannotated 3' ends). If the transcripts ends differed from the 
3' ends of the IpA isoforms, then we defined the 3' end determined from the 3'-seq to 
be the real end. This was done as 3'-seq identifies 3' ends of polyadenylated mRNAs at 
a single nucleotide resolution and thus position of these ends would be much more 
accurate than the ends of transcripts obtained from transcript assembly. Figure 6.1.1 
shows an assembled transcript for CCT4 IpA isoform. 
		
Figure 6.1.1: Assembled transcript for the IpA isoform of CCT4 
The green transcript was assembled through de novo assembly using RNA-seq data. 
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Coding potential prediction Our goal was to determine the probability that the 5' IpA 
events were non-coding transcripts. To accomplish this aim, we made use of CPAT, a 
coding potential assessment tool that predicts the coding potential of the transcript 
based on four sequence features: open reading frame size, open reading frame 
coverage, Fickett TESTCODE statistic and hexamer usage bias (Wang et al. 2013). 
Once the coding potential of the transcripts was predicted, we found that early ending 
transcripts had a lower probability to be coding, as we hypothesized (Figure 6.1.2). 
This implied that the 5' IpA events have a higher probability to be non-coding RNAs. 
For the remaining analysis we considered non-coding IpA isoforms to be the ones that 
had coding potential probability less than 0.3 and had retained coding sequence less 
than 25% (n = 711). These putative non-coding 5' IpA isoforms could be involved in 
various functional roles. A number of studies have shown that non-coding RNAs 
generated from the gene locus critically regulate the same gene (Han et al. 2007; 
		
Figure 6.1.2: Most of the transcripts retaining less than 25% of the coding 
sequence are predicted to be non-coding 
The transcripts that retain less than 25% of the coding sequence of the complete transcript have 
very low probability to be translated into protein. 
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Martianov et al. 2007; Schmitz et al. 2010; Di Ruscio et al. 2013). From our results, 
the presence of non-coding RNAs across a large pool of genes suggests that this 
phenomenon of cis-regulation could be more widespread than previously appreciated.  
 
6.2 Non-coding IpA isoforms enriched for binding sites of RNA 
binding proteins 
 
Over the years a number of independent studies have established the role of different 
long non-coding RNAs (lncRNAs) involved in regulating development and 
differentiation (Fatica and Bozzoni 2014). A highly studied case is role of lncRNAs in 
X chromosome inactivation and genomic imprinting. Three different lncRNAs, X-
inactive specific transcript (Xist), Kcnq1 overlapping transcript 1 (Kcnq1ot1) and Airn 
(antisense Igf2r (insulin-like growth factor 2 receptor) RNA) co-ordinate to establish 
repressive chromatin (Lee and Bartolomei 2013). They do so by the recruitment of 
DNA methyltransferase 3 (DNMT3), which induces DNA methylation; Polycomb 
repressive complex 2 (PRC2), which produces histone H3 lysine 27 trimethylation 
(H3K27me3); and histone lysine N-methyltransferase EHMT2, which is responsible 
for producing H3K9me2 and H3K9me3. Another case of cis regulation by a lncRNA 
is the HOXA distal transcript antisense RNA (HOTTIP), which is generated from the 
5' tip of the HOXA locus (Wang et al. 2011). HOTTIP recruits the MLL1 complex 
leading to deposition of the active H3K4me3 mark. LncRNAs have also been shown 
to play a crucial role in trans-regulation. A well-studied case for trans-regulation is the 
recruitment of two repressive complexes, PRC2 and the H3K4 demethylating complex 
over the HOXD genes by HOXA transcript antisense RNA (HOTAIR) (Rinn et al. 
2007). Encouraged by these examples of lncRNA-mediated gene regulation, we 
wanted to investigate if the IpA isoforms that we predict to be non-coding RNAs 
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could have the ability to recruit RNA binding proteins and play a role in regulation. 
We were particularity interested to find out if the IpA isoform gained intronic 
sequence, that was enriched with RNA binding protein sites.  
 
To investigate our hypothesis, we used available RBP CLIP (cross-linking 
immunoprecipitation) data from different studies. The different CLIP protocols are 
next-generation sequencing based assays that provide a transcriptome-wide map of 
RNA binding proteins sites. A majority of CLIP studies have been done in a cell line 
derived from human embryonic kidney cells (HEK293). We obtained the binding site 
information from a resource database, doRiNA that provides processed CLIP 
experimental results from many different studies (Blin et al. 2015). As the binding site 
information is only available for HEK293 cells, we focused on the non-coding IpA 
isoforms expressed in HEK293.  Only IpA isoforms that had the gained part of an 
intron longer than 50nt were used for the analysis (IpA isoforms = 79, genes = 72). 
We wanted to determine if this gained part of the intron was enriched for RNA 
binding protein sites compared to the other introns of the same genes that were not 
included in the non-coding isoforms. The entire length of the gained part of the non-
coding isoform and the other introns was converted into windows of lengths 50 nts. 
For every CLIP experiment, we determined the probability of having a binding site in 
the other introns (background) to get the expected number of binding sites in the 
gained part of the non-coding IpA isoforms (expected value). Using the expected and 
observed number of sites we calculated the binomial Z-score of each CLIP 
experiment. We repeated the same procedure to get the binomial z-score with coding 
exons of the same genes as background. We found that these gained parts of the 
introns are enriched for various RBP binding sites. The RBPs for which the Z-score ≥ 
10 with other introns as the background and Z-score ≥ 2 with coding sequence as the 
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background were the RBPs that could potentially be recruited by these non-coding 
IpA isoforms (PUM2, FUS, AGO2, LIN28B, HUR, ZC3H7B, TIAL1, TAF15 and 
TIA1). Figure 6.2.1 shows IpA isoform of CUL1 with binding sites for RBPs. This 
observation suggests that the non-coding IpA isoforms could potentially recruit RBPs 
to the same gene locus, to a target locus in trans, or to some other subcellular 
compartment.			
	
6.3 IpA isoforms potentially diversify proteome but largely do not 
affect the transcriptional activity of the genes 
 
Transcriptional activity of genes is largely unaffected by expression of IpA 
		
Figure 6.2.1: Gained part of intron in non-coding IpA isoforms is enriched for 
RBP sites 
The gained part of intron in the non-coding IpA isoforms is enriched for RNA binding protein sites 
compared to the other introns of the same genes. This shows an example of a non-coding IpA isoform 
of CUL1 that has gained part of the second intron. The gained part has binding sites for PUM2, AGO2 
and ZC3H7B. 
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isoforms One of the most intuitive functions of the IpA isoforms could be to change 
the full-length expression of the genes. Previous studies have suggested that higher 
expression of IpA isoforms would cause switch-like reduction of expression of the 
full-length transcript (Tian et al. 2007; Andersen et al. 2012). We also hypothesized 
that expression of IpA isoforms would lead to repression of the full-length expression 
of the genes and vice-versa. To test this hypothesis, we compared expression of the 
full-length transcript between two conditions (naïve B cells (blood) vs naïve/CD5+ B 
cells (tonsil), CLL group 1 vs N5, MM group 1 vs PC) for all the expressed genes with 
IpA isoforms. Contrary to our hypothesis we found that in all three comparisons less 
than half of IpA isoforms (38% in B cells, 20% in CLL group 1 and 49% in MM 
		
Figure 6.3.1: Transcriptional activity of genes largely unaffected by expression 
of IpA isoforms 
Less than 50% of genes show increase/decrease in the full-length transcriptional activity by the 
differential usage of the IpA site. This figure shows the fold change of the IpA isoform and the full-
length isoform in naïve B cells (blood) vs naïve/CD5 + B cells (tonsils). The genes that have IpA 
isoforms with significantly different usage (adjusted p < 0.1 and difference in usage < 0.1) of the 
IpA site are highlighted in red, green, purple or blue. Red genes: Full-length express was 
downregulated with high expression of IpA isoforms; green genes: IpA isoform was expressed 
without any effect on the full-length isoform expression; blue genes: Loss of expression of IpA 
isoform caused upregulation of the full-length isoform and purple genes: Loss of usage of IpA site 
had no effect on the expression of full-length isoform. 
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group 1) appeared to have affected the full-length expression (Figure 6.3.1). This 
observation indicates that the expression of majority of IpA isoforms is independent 
from the expression of the full-length transcript, contrary to previous reports (Tian et 
al. 2007; Andersen et al. 2012).  
 
IpA isoforms contribute towards diversification of proteome Our previous results 
in Section 6.1 suggest that IpA isoforms retaining more than 25% of coding sequence 
(n = 3240) likely have a higher potential to be translated into protein. IpA isoforms 
that end in the same intron were treated as one case. These IpA isoforms would still 
create proteins that are different from the proteins generated from the full-length 
mRNAs. Such IpA isoforms would have lost certain protein domains due to early 
cleavage, like the IgM gene or the receptor tyrosine kinases (Early et al. 1980; Rogers 
	
Figure 6.3.2: IpA can potentially diversify proteome 
Usage of IpA sites creates mRNA that would be translated into proteins different than the full-length 
isoforms. This figure shows the different domains that are present in the genes that express IpA 
isoforms. It shows the number of IpA isoforms that loose one of these domains and would potentially 
contribute towards diversification of proteome. 
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et al. 1980; Vorlova et al. 2011). If a transcription factor mRNA isoform loses a DNA-
binding domain or an enzyme mRNA isoform loses the active site, then such isoforms 
would create proteins that differ significantly in their function. We believe that IpA 
could be a way to diversify the proteome. To get an assessment of the protein domains 
that are lost from the IpA isoforms, we determined the distribution of IpA isoforms 
that loose one of the important domains. The IpA isoforms that retained more than 
25% of their coding sequence were used for the analysis. We found that 50% of such 
isoforms (n = 1657) have at least one of the following domains: transmembrane 
domain, an active site, a protein-protein interaction domain, DNA binding domain, 
kinase domain, lipid binding region, fiber, RNA-binding domain or channel. Amongst 
these more than half of IpA isoforms (61.19%) loose at least one of the above domains 
(n = 1014). Figure 6.3.2 shows the distribution of loss of these domains by the IpA 











7. SUMMARY AND CONCLUSION 
 
To my knowledge our study is the first to investigates the usage of IpA site on a 
genome-wide level across diverse tissue and cell types. In this dissertation we 
characterized IpA isoforms across a wide variety of human cell types and B cell 
malignancies. We made use of high throughput 3' end sequencing to gain a finer 
understanding of the usage of IpA sites, its contribution to generate non-coding RNAs 
and alternative protein isoforms, and the functional importance of these IpA isoforms. 
We carefully created an atlas of IpA isoforms that are robustly expressed in the 
various cell types. We also investigated various properties of these IpA isoforms and 
their potential functional consequences. Using the atlas, we learned how the landscape 
of IpA isoform expression changes across different normal cellular conditions and in 
B cell malignancies compared to the normal cell type of origin. We also tried to 
understand how the differentially expressed IpA isoforms could potentially contribute 
to tumorigenesis by mimicking somatic alterations. A summary of our findings from 
this study is presented below: 
 
7.1 Atlas with robustly expressed IpA isoforms across a wide variety 
of tissue and cell types 
 
We performed a high throughput sequencing protocol called 3'-seq that precisely 
identifies the 3' ends of the transcripts on a global level over a large number of cell 
types and tissue. 3'-seq is a highly quantitative, tag-based sequencing approach that 
provides an accurate quantification of the relative expression of 3' end isoforms. Using 
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3'-seq, we created an atlas of robustly expressed IpA isoforms across diverse tissues, 
normal immune cells, and B cell malignancies. The pipeline for creating the atlas 
accounted for all known potential artifacts and used various steps to filter out spurious 
IpA isoforms. Cases where the genomic context was complicated and it was difficult 
to assign isoforms to a single gene with high confidence were also removed. At the 
end, IpA isoforms that were potentially produced by “transcriptional noise” and 
unlikely to produce highly expressed non-coding RNAs or alternative coding isoforms 
were filtered out, leaving only robust cleavage events in the atlas. This atlas became 
the basis of all the future analysis. Similar to an earlier study that mapped pASs using 
cDNA/ESTs on the human genome (Tian et al. 2007), we found usage of IpA sites in 
approximately 23% of expressed genes in wide variety of tissue and cell types. 
 
7.2 IpA isoforms are expressed as part of the normal expression 
program with variable expression patterns in different cell types 
 
We found out that the fraction of genes expressing IpA isoforms varies between 
different cell types. Immune cells have a higher proportion of expressed genes with 
intronic cleavage events compared to solid tissues. Variability in the usage of IpA sites 
in different cell lines has also been reported previously (Tian et al. 2007). We 
observed almost no IpA isoforms that were uniquely expressed in a single tissue. 
Rather, the majority of IpA isoforms are expressed in at least two cell types where the 
gene is expressed. The tissue-specific isoforms are expressed in tissue-specific genes 
of the particular tissue type. Since IpA isoforms are robustly expressed and regulated 
across normal cells, usage of IpA sites should be viewed as part of the normal 
expression program. Regulated usage of IpA site in the heavy chain IgM gene in the B 
cell maturation pathway is one of the classic case of intronic alternative cleavage and 
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polyadenylation (Early et al. 1980; Rogers et al. 1980). However, since then very few 
studies have appreciated the potential of intronic cleavage and polyadenylation to 
serve as a layer of gene regulation. Amongst these studies, the few well known cases 
where the regulation of IpA site plays a role in generating different protein isoforms 
are calcitonin/calcitonin gene-related peptide genes (CALCA), transcriptional factor 
SREPF and FLT1 (Wang et al. 2006; Thomas et al. 2007). There have been some 
studies describing the usage of IpA sites as recognition of cryptic polyadenylation 
sites or a premature cleavage and polyadenylation event that should not occur in 
normal circumstances (Kaida et al. 2010; Berg et al. 2012). Thus, our study is critical 
in establishing that IpA isoforms are not generated by noisy or undesired usage of 
cryptic pAS in the introns, as previously believed. A recent study has described 
generation of new alternative 3' ends in introns by exonisation of Alu elements (Tajnik 
et al. 2015). Similar to our observation, this study describes the usage of these IpA 
sites to be tissue-specific. We found the expression of a large number of IpA isoforms 
to be tightly regulated between the same cells obtained from different cellular 
environments (naive B cells from tonsils and blood) obtained from different cellular 
environments. We found an example of a differentially regulated IpA isoform of 
SPTBN1, which is translated into two different protein isoforms that might have a 
direct role in defining cellular shape in these different cellular environments. The 
strong regulation of expression of IpA isoforms between normal cell types provides 
evidence of their functional role.  Levels of hnRNP C and U2AF65 have been shown 
to play a role in defining the usage of IpA sites originating by Alu exonisation (Tajnik 
et al. 2015). We also believe that the level of the factors involved in splicing and 
cleavage would play a pivotal role in determining the usage of IpA sites in wide 
variety of tissue and cell types. Multiple studies have suggested an interplay between 
splicing and alternative cleavage, specifically pASs located in the introns of the genes 
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(Tikhonov et al. 2013; Movassat et al. 2016). A systematic screening of the splicing 
machinery and cleavage factors is required to identify the key players involved in the 
usage of the IpA sites.  
 
7.3 Diverse pattern of usage of IpA sites along transcription units in 
various tissue and cell types  
 
The positions where the intronic cleavage events take place are critical, as they define 
the protein that would be translated from the IpA isoforms. We observed that there is a 
higher tendency for the IpA isoforms to have their cleavage sites close to the 5' UTR 
of the transcription unit, thus retaining at most a small portion of the coding sequence. 
However, this positional preference of IpA sites varies between different cell types. 
The majority of IpA isoforms expressed in tissues like ovary and brain use IpA sites 
located close to the 3' end of the transcription unit (3' IpA events). Such isoforms 
would be translated into alterative protein isoforms due to loss of 3' terminal exons. 
Cell types like T cells and plasma cells have most of the 3' ends of the IpA isoforms in 
early introns close to the start of the transcription unit (5' IpA events). We also 
observed that cell types with a higher fraction of genes expressing IpA isoforms also 
have a higher number of 5' IpA events. This indicates that cell types that express a 
higher number of IpA isoforms tend to increase the usage of IpA sites near the start of 
the transcription unit. The controlled usage of IpA sites in different tissue types 
suggests that these IpA isoforms potentially create wide variety of mRNAs that might 
be involved in functional roles. Additionally, we observed a correlation between the 
length of the 3' UTRs and the proportion of IpA isoforms that are expressed across cell 
types.  We found that the tissues with shorter 3' UTRs have higher proportion of genes 
with IpA isoforms. This observation suggests that the factors involved in defining the 
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length of 3' UTRs potentially also play a role in regulating the usage of IpA sites. 
 
7.4 Retained introns are associated with the occurrence of IpA events 
 
Utilizing the RNA-seq data we found that IpA events are enriched in introns that are 
retained. We also observed that the tissues and cell types with a higher number of 
retained introns had a higher fraction of genes with IpA isoforms. This observation 
suggests of an association between the two processes: intron retention and IpA. We 
hypothesize that retention of the intron could facilitate the recognition of an IpA site 
by the cleavage machinery leading to the formation of the 3' end. Splicing machinery 
factors have been shown to be involved in retention of intron (Wong et al. 2013). In 
particular, expression levels of factors that define the exon junctions, U5, U4/U6, U1, 
U2, U2AF along with SR proteins affect the intron retention levels. We believe that 
the expression levels of these factors in conjunction with cleavage and 
polyadenylation machinery factors might be important in defining the usage of IpA 
site. 
 
7.5 Genes with long transcription units, long introns and long 5' 
UTRs are enriched with pASs and devoid of U1 snRNP signals to 
facilitate intronic cleavage events 
 
We observed that genes with IpA events have a special genomic architecture along 
with a different sequence composition that together facilitate the formation of 3' ends 
in introns. We found that IpA events are most prevalent in longer transcription units 
that have long introns. Occurrence of higher usage of IpA sites in long introns in 
humans has also been reported previously (Tian et al. 2007). Similar to our results, 
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usage of IpA sites in long introns of genes in Arabidopsis Thaliana has been observed 
(Guo et al. 2016). These genes also have longer 5' UTRs in comparison to the genes 
that do not express IpA isoforms. This observation of higher incidence of recognition 
of IpA sites in long introns asserts that the long introns provide an increased 
opportunity for the cleavage machinery to define a cleavage event. Apart from these 
architectural features, the genes that express IpA isoforms also differ in their sequence 
composition. There is a higher frequency of pASs in these genes while these genes are 
depleted for U1 snRNP signals. The combination of the presence and absence of these 
two kinds of signals makes these genes ideal candidates to express IpA isoforms. U1 
snRNP has been shown to play a crucial role in preventing premature cleavage and 
polyadenylation while recognition of pASs leads to a 3' cleavage event (Kaida et al. 
2010; Berg et al. 2012). Thus the genes that express IpA isoforms have special 
architectural and compositional features in comparison to the genes that always make 
full-length isoforms. However, it is important to realize that the usage of these IpA 
sites is regulated strongly between cell types, resulting in varied expression of IpA 
isoforms across different tissue and cell types. To establish this more firmly we would 
need to measure the levels of U1 snRNP in our samples to affirm the role of U1 
snRNP is recognition of IpA sites. 
 
7.6 Intronic cleavage events creates a wide variety of mRNAs with 
potentially diverse functions 
 
In our atlas, the majority of IpA isoforms use an IpA site close to the start of the 
transcription unit, retaining at most a small fraction of the coding sequence. We 
established that there is a higher probability for these early ending IpA isoforms to be 
non-coding mRNAs. Other studies have demonstrated the role non-coding RNAs 
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generated from the gene locus in regulation of genes (Martianov et al. 2007; Di Ruscio 
et al. 2013). We also investigated the potential role of these non-coding mRNAs in 
cis/trans gene regulation. We found that intronic sequences that become part of the 
non-coding transcript are enriched for binding sites of RNA binding proteins 
compared to the other introns of the genes that were not incorporated in the IpA 
isoform. This enrichment of binding sites for RNA binding proteins may suggest a 
potential role of these non-coding IpA isoforms in gene regulation. The IpA isoforms 
with cleavage sites near the 3' end of the transcription unit lose C-terminal exons. 
Such mRNAs would create proteins with altered functions and would potentially 
contribute towards diversifying the proteome. Loss of important protein domains like 
the active site of an enzyme or a DNA-binding domain of a transcription factor could 
also make the protein dysfunctional. We hypothesized in the beginning of the study 
that the likefest function of non-coding IpA isoforms would be to regulate the 
expression of full-length isoforms. However, by comparing various conditions, we 
found that the full-length transcript expression level is only affected by an 
increase/loss in usage of the IpA sites in less than 50% of genes. This observation 
suggests that in a majority of cases the expression of IpA isoforms is independent of 
the expression of the full-length isoform. 
 
7.7 Truncated mRNAs generated by the usage of IpA sites can mimic 
genetic mutations 
 
We examined the change in landscape of usage of IpA sites in chronic lymphocytic 
leukemia compared to naïve and CD5+ B cells obtained from tonsils. We found a 
group of CLL samples to have significantly higher usage of IpA sites relative to full-
length isoforms. We hypothesized that in cancer, IpA isoforms could have the 
	 97	
potential to contribute to tumorigenesis by mimicking genetic alterations like loss-of-
function mutations, chromosomal translocations or deletions. The IpA isoforms 
creating alternative protein isoforms by loss of C-terminal exons could potentially 
mimic loss-of-function mutation or chromosomal translocation, while the IpA 
isoforms resulting in non-coding RNAs could mimic the deletion of a gene. We 
investigated this hypothesis in CLL and indeed found that a subset of genes with 
truncating mutations in CLL also have increased usage of IpA sites relative to the full-
length isoform. Strikingly, we found that a much higher proportion of CLL patients 
express IpA isoforms compared to the proprtion that harbor truncating mutations. This 
finding suggests that the cancer cells might use IpA as an alternative mechanism to 
achieve proliferation and survival in absence of a somatic mutation.  We confirmed 
this finding by showing that the truncated protein created by IpA isoforms is similar to 
the truncated protein created by identified mutations in the MGA gene. Another study 
has demonstrated the recognition of IpA site to generate MAGI3 truncated protein in 
human breast cancer (Ni and Kuperwasser 2016). This truncated protein acts a 
dominant-negative oncogene promoting the malignant transformation human 
mammary epithelial cells. Our results also suggest that usage of IpA sites could lead to 
creation of protein isoforms contributing towards tumorigenesis in CLL. We also 
examined the change in usage of IpA sites in multiple myeloma. In contrast to CLL, 





In this dissertation we conducted an in-depth analysis of 3' end sequencing libraries to 
characterize the IpA isoforms across a wide variety of tissue and cell types. With this 
	 98	
analysis we were able to establish that IpA isoforms are expressed and regulated as a 
part of the normal expression program in human cells. These IpA isoforms represent a 
wide variety of mRNAs that could potentially have diverse functions. Truncated 
transcripts generated by IpA could create alternative protein isoforms with altered 
functions or create non-coding RNAs that potentially serve as a layer of gene 
regulation. This study provided evidence that cancer cells can regulate the usage of 
IpA sites to mimic genetic mutations, providing an alternative mechanism for 
activated oncogenic expression programs. Overall this study contributes significantly 
towards a better understanding of potential functional role of IpA sites in normal and 
cancer cells. 
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